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Cardiovascular diseaseCardiovascular disease is the leading cause of death worldwide. Despite advancements in diagnosis and treat-
ment of cardiovascular disease, the incidence of cardiovascular disease is still rising. Therefore, new lines of med-
ications are needed to treat the growing population of patients with cardiovascular disease. Although the
majority of the existing pharmacotherapies for cardiovascular disease are synthesized molecules, natural com-
pounds, such as resveratrol, are also being tested. Resveratrol is a non-ﬂavonoid polyphenolic compound,
which has several biological effects. Preclinical studies have provided convincing evidence that resveratrol has
beneﬁcial effects in animal models of hypertension, atherosclerosis, stroke, ischemic heart disease, arrhythmia,
chemotherapy-induced cardiotoxicity, diabetic cardiomyopathy, and heart failure. Although not fully delineated,
some of the beneﬁcial cardiovascular effects of resveratrol are mediated through activation of silent information
regulator 1 (SIRT1), AMP-activated protein kinase (AMPK), and endogenous anti-oxidant enzymes. In addition to
these pathways, the anti-inﬂammatory, anti-platelet, insulin-sensitizing, and lipid-lowering properties of resver-
atrol contribute to its beneﬁcial cardiovascular effects. Despite the promise of resveratrol as a treatment for nu-
merous cardiovascular diseases, the clinical studies for resveratrol are still limited. In addition, several conﬂicting
results from trials have been reported,which demonstrates the challenges that face the translation of the exciting
preclinical ﬁndings to humans. Herein, wewill reviewmuch of the preclinical and clinical evidence for the role of
resveratrol in the treatment of cardiovascular disease and provide information about the physiological and mo-
lecular signaling mechanisms involved. This article is part of a Special Issue entitled: Resveratrol: Challenges in
translating pre-clinical ﬁndings to improved patient outcomes.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Cardiovascular diseases (CVDs) are a class of diseases that affect the
heart and/or the blood vessels [1]. Themost common examples of CVDs
include hypertension and coronary artery disease (CAD). Of the 83.6
million American adults with CVD, ~93% are hypertensive and ~18%
have atherosclerosis [2]. If left untreated or with poor clinical manage-
ment, hypertension and/or atherosclerosis can develop into arrhyth-
mias, ischemic heart disease, myocardial infarction, and eventually,
heart failure [2]. The World Health Organization (WHO) ranks CVDs as
the leading cause of death worldwide—with an estimated 17.3 million
people dying of CVD annually [1]. The incidence of CVD is expected to
continue to rise and along with the increase in disease prevalence, the
expected worldwide CVD-related deaths are projected to climb to 23.3
million by 2030. Based on these statistics, it is apparent that newatrol: Challenges in translating
ch Centre, University of Alberta,
14; fax: +1 780 492 9753.therapies are needed to combat the enormous burden of CVDs on the
quality and length of life of the global population.
Resveratrol (3,5,4′-trihydroxy-trans-stilbene) is a non-ﬂavonoid
polyphenolic compound belonging to the stilbene group [3]. It is
found in many plant based foods and beverages including red wine,
grapes, a variety of berries, and peanuts [4]. Resveratrol is considered
a phytoalexin because it is produced by the plant under stress condi-
tions [5]. Although resveratrol exists in either the cis or trans form, it is
the trans isomer that is amore effective anti-oxidant [6] and ismore bio-
active [7], andmore stable [7,8]. The presence of resveratrol, alongwith
other polyphenolic compounds in red wine has garnered much atten-
tion, especially with regard to their potential role in the protection
against CVD [9]. Indeed, red wine is thought to be responsible for the
“French Paradox”, a term used to describe the low incidence of CVD in
the French population despite their high intake of saturated fats [10].
However, resveratrol is present at very low concentration in red wine
[11], suggesting that the French Paradox is mediated through several
dietary and life-style factors not through resveratrol alone. In fact, al-
though resveratrol is present in foods and beverages, the concentrations
are quite low and research into resveratrol has largely involved resver-
atrol supplements [12,13]. Regardless of whether or not the French
Paradox involves resveratrol, the antiplatelet activity of resveratrol
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following 20 years, a plethora of preclinical studies have demonstrated
the beneﬁcial effects of resveratrol in the prevention and/or treatment
of several CVDs in various animal models [4]. Similarly, mechanistic
studies have identiﬁed a multitude of molecular targets for resveratrol
[15]. Nevertheless, the conﬁrmation of these promising effects in
human clinical trials is still very limited with several inconsistent
ﬁndings and a few unfavorable results [16].
The objective of this review is to discuss the current knowledge
about the potential beneﬁcial effects of resveratrol in several CVDs,
including hypertension, atherosclerosis, ischemic heart diseases, heart
failure, arrhythmia, and stroke. The review will discuss important mo-
lecular targets of resveratrol implicated in its cardiovascular protective
effects. Thereafter, the results of preclinical studies will be compared
to those of recent clinical studies that show the cardiovascular effects
of resveratrol in humans. The challenges that face translating the pre-
clinical ﬁndings to clinical settings will also be discussed.2. Hypertension
Hypertension has been shown to be amajor risk factor for CVDs [17].
The prevalence of hypertension is estimated to bemore than 25% of the
adult population in developed countries [18] and in the United States,
approximately 33% of the adult population over the age of 20 have
hypertension [2]. Although there are several classes of drugs used toTable 1
The anti-hypertensive effects of resveratrol in animal models.
Model Resveratrol dose Duration
Angiotensin II infused mice 320 mg/kg/day mixed with diet 2 weeks
SHR 146 mg/kg/day mixed with diet 5 weeks
Early weaning rat offspring 30 mg/kg/day by oral gavage 30 days
High fructose corn syrup 50 mg/L in drinking water 10 weeks
Rats fed High fat diet 2.5 mg/kg/day by oral gavage 6 weeks
Rat model of preeclampsia 20 mg/kg/day, by orogastric route Throughout pregn
SHR 50 mg/L in drinking water
(5 mg/kg/day)
10 weeks
Estradiol-17β-induced
hypertension
in female rats
0.84 g/kg diet 41 days
Two-kidney, one-clip hypertensive
rat
10 mg/kg/day IP 6 weeks
SHR 2.5 mg/kg/day by oral gavage 10 weeks
Angiotensin II in transgenic rats 800 mg/kg/day by gavage 4 weeks
Obese Zucker rats 10 mg/kg/day by oral gavage 8 weeks
High fat diet — female rats 20 mg/kg/day mixed with diet 8 weeks
Partially nephrectomized rats 50 mg/kg/day by oral gavage 4 weeks
Fructose 10% in drinking water 10 mg/kg/day by oral gavage 45 days
Ovariectomized female rats 5 mg/kg/day 3 weeks
SHR 0.448 mg/L 4.44 mg/L in drinking
water
4 weeks
DOCA-salt hypertensive rats 1 mg/kg/day orally 4 weeks
Angiotensin II-infused mice 4 g/kg diet (320 mg/kg/day) 2 weeks
10% fructose-fed rats 10 mg/kg/day 2–4 weeks
Pulmonary hypertension
Monocrotaline-induced pulmonary
hypertension
25 mg/kg/day in drinking water 14 or 21 days, st
one
day post monocr
Monocrotaline-induced pulmonary
hypertension
10–30 mg/kg i.g. twice daily 21 days, starting
monocrotaline
Monocrotaline-induced pulmonary
hypertension
3 mg/kg/day in drinking water 14 days, starting
post monocrotal
PTE-induced acute pulmonary
hypertension
10 mg/kg IP Two doses, 1 h b
start of the PTE,
for another 8 htreat hypertension, the target blood pressure (BP) values may not
be achieved in some patients even after combining 3 or more anti-
hypertensive medications [19]. In addition, not all anti-hypertensive
medications can protect against the end-organ damage commonly
observed in hypertensive patients (e.g. cardiac hypertrophy, hyperten-
sive nephropathy, cerebrovascular complications, and hypertensive
retinopathy [20]). Therefore, there is still a clinical need for an anti-
hypertensive medication that can safely lower BP as well as offer end-
organ protection. Of importance, several investigators have demon-
strated that resveratrol can lower BP in experimental animal models
of hypertension (Table 1). In addition, resveratrol can offer end-organ
protection due to its cardioprotective [21], nephroprotective [22], neu-
roprotective [23], and retinoprotective properties [24]. Based on these
studies, resveratrol may be a promising anti-hypertensive medication
warranting further investigation.2.1. Preclinical studies
The anti-hypertensive effect of resveratrol (10–320 mg/kg body
weight/day) has been demonstrated in several animal models of hyper-
tension including the spontaneously hypertensive rat (SHR) model [25,
26], the angiotensin (Ang) II infused mouse model [25,27], the two-
kidney one-clip hypertensive rat [28], and in partially nephrectomized
rats [29]. In general, lower doses of resveratrol (2.5 mg/kg/day) did
not affect BP in several other studies performed in the same animalEffect on blood pressure Ref
Reduced SBP [25]
Reduced SBP [25]
Reduced SBP, DBP, triglycerides, and LDL-cholesterol [314]
Reduced SBP, triglycerides, and total cholesterol [35]
No effect on BP. Improved diastolic function in obese prone rats [315]
ancy No effect on BP [316]
Reduced SBP, DBP, and heart weight/body weight ratio [26]
Reduced SBP and DBP [317]
Reduced BP, ameliorated cardiac hypertrophy, and improved left
ventricular function
[28]
No effect on BP [39]
Reduced BP, ameliorated cardiac hypertrophy, and partially
prevented
angiotensin-II induced coronary and myocardial damage
[215]
Reduction in SBP. Reduction in plasma levels of total cholesterol
and triglycerides
[34]
Reduced BP [38]
Reduced SBP and heart weight [29]
Reduced SBP, and alleviated cardiac hypertrophy [36]
Reduced SBP [37]
No effect on BP [40]
Reduced systolic BP [33]
Reduced Systolic BP [27]
Reduced SBP [67]
arting
otaline
Prevented the increase in right-ventricular systolic pressure,
and right-ventricular hypertrophy
[70]
after the Dose-dependent amelioration of right ventricle free wall
thickness, right ventricular systolic
pressure, and decreased pulmonary arterial acceleration
[69]
28 days
ine
Reversed established pulmonary hypertension (attenuated right
ventricular
systolic pressure, and right ventricular hypertrophy)
[71,72]
efore the
and then
Pre-treatment with resveratrol signiﬁcantly reduced mean
pulmonary artery pressure
[73]
Fig. 1. Proposed mechanisms of the anti-hypertensive effect of resveratrol. The anti-
hypertensive effect of resveratrol is mediated through activation of AMP-activated
protein kinase (AMPK), silent information regulator 1 (SIRT1), and nuclear factor ery-
throid-2 related factor 2 (NRF2), which leads to both endothelium-dependent and endo-
thelium-independent vasorelaxation. Multiple cross-talks exist among these pathways.
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anti-hypertensive effects of resveratrol are dose-dependent, resveratrol
(1 mg/kg/day) has been shown to reduce BP in DOCA-salt hypertensive
rats [33], suggesting that under certain conditions, even low doses of
resveratrol can lower BP and that the BP lowering effect of resvera-
trol is model-dependent. Indeed, relatively low doses of resveratrol
(5–10 mg/kg/day) were sufﬁcient to lower BP in hypertension ani-
mal models associated with insulin resistance [34–37], suggesting
that resveratrol may be more effective in lowering BP in patients
with diabetes or metabolic syndrome. In agreement with this, res-
veratrol treatment (10 mg/kg/day) reduced systolic BP in obese
Zucker rats, yet had no effect on the BP of lean rats [34]. Similarly,
resveratrol treatment (20 mg/kg/day) signiﬁcantly lowered systolic
and diastolic BPs in female rats fed high fat diet, but not in rats fed
normal chow diet [38].
In an effort to understand the potential of resveratrol to augment the
effect of other anti-hypertensive medications, Thandapilly et al. admin-
istered low dose resveratrol with and without hydralazine to SHR [31].
Although a low dose of resveratrol (2.5 mg/kg/day) alone did not affect
the systolic or the diastolic pressure in the SHR [31,39], the combination
of hydralazine and resveratrol treatment was signiﬁcantly more effec-
tive than hydralazine alone in reducing both systolic and diastolic BPs
[31]. Although these ﬁndings are important, hydralazine is rarely used
in the clinic to treat hypertension. As a result, to translate these ﬁndings
to humans, it will be essential to conﬁrm these interesting ﬁndings with
more commonly prescribed anti-hypertensive medications such as an-
giotensin converting enzyme (ACE) inhibitors, angiotensin receptor
blockers, Ca2+ channel blockers, beta blockers, and thiazide diuretics
as well as understand the mechanism(s) involved.
Interestingly, some studies that did not report a BP lowering ef-
fect of resveratrol have still demonstrated other protective effects
on the vasculature. For instance, low dose resveratrol treatment
(0.448 mg/L to 4.48 mg/L in drinking water) did not reduce systolic
BP in SHR, but it improved endothelium-dependent relaxation to
acetylcholine (Ach) in thoracic aortic rings from hypertensive SHRs
[40]. Similarly, resveratrol treatment (50 mg/L in drinking water
for 3 weeks) has also been shown to increase Ach-induced relaxa-
tion and decrease phenylephrine- and Ang II-induced contraction
in endothelium-intact aortic rings of healthy male and female rats
[41]. Nevertheless, resveratrol had no effect on endothelium-
dependent relaxation in thoracic aortic rings from normotensive
Sprague–Dawley rats [40], suggesting a more pronounced effect on
damaged vessels compared to healthy ones.
Since age, obesity, anddiabetes are important risk factors for endothe-
lial dysfunction [42], resveratrol treatment (2400 mg/kg of food) has
been shown to prevent both age-related and obesity-related declines in
endothelial function [43]. For instance, the maximal relaxation to Ach
was improved by about 75% in diabetic rabbits treated with resveratrol
(50 mg/L of drinking water) [44]. Moreover, resveratrol suppressed
basal superoxide production and lipid peroxide levels in the aortas of
diabetic rats protecting the endothelial integrity fromdiabetes. Of impor-
tance, these protective effects occurred in the absence of changes in blood
glucose or lipids [44]. Overall, the protective effect of resveratrol on the
vasculaturemay play an important role in the prevention of hypertension
and/or in the protection against hypertension-induced end organ dam-
age in the long-term.
The anti-hypertensive effect of resveratrol is thought to bemediated
through both endothelium-dependent and endothelium-independent
mechanisms (Fig. 1) [45]. With regard to its endothelium-dependent
effects, resveratrol supplementation has been shown to improve ﬂow-
mediated vasodilation, a surrogate for endothelial function, in several
animal models [28,40,41,43]. Similarly, resveratrol has been shown to
stimulate endothelium-dependent relaxation of isolated carotid arteries
[46] and aortic rings [47]. These endothelium-dependent vasodilatory
effects of resveratrol appear to bemediated via improved bioavailability
of nitric oxide (NO) through increasing endothelial nitric oxide synthase(eNOS) expression and activity [48,49]. NO is generated by three
isoforms of NO synthase (NOS), eNOS, neuronal NOS (nNOS), and
inducible NOS (iNOS) [50]. eNOS is of particular importance in cardio-
vascular physiology as it regulates vascular tone via the release of
NO in the vascular endothelium [50]. The mechanisms for increased
NO bioavailability during resveratrol treatment have been proposed
to involve the effects of resveratrol on silent information regulator 1
(SIRT1), AMP-activated protein kinase (AMPK), and reactive oxygen
species (ROS).
SIRT1 is a class III histone deacetylase responsible for various biolog-
ical effects including the stimulation of NO production by deacetylating
eNOS at lysine residues [51]. In addition, a resveratrol-induced increase
in eNOS expression has been attenuated by knocking-down endoge-
nous SIRT1 levels by RNAi [52], and thus it appears that SIRT1 activation
by resveratrol mediates both activity and expression of eNOS. AMPK, a
major regulator of energy metabolism [53], also regulates NO bioavail-
ability via eNOS. AMPK can directly phosphorylate and activate eNOS
on serine 1177, resulting in a subsequent increase in NO production
[54]. It has been shown that resveratrol activates AMPK to stimulate
NO production [25]. The dependence of AMPK in this process has been
demonstrated with pharmacological inhibition of AMPK that also
abolished the ability of resveratrol to improve endothelium-dependent
vasodilation in aortic rings [47], and resveratrol-induced eNOS activation
in humanumbilical vein endothelial cells (HUVECs) [25]. Of interest, a re-
cent study has shown that administration of the AMPK inhibitor, com-
pound C, signiﬁcantly reduced the beneﬁcial effect of resveratrol on
lowering BP in Ang II-infused mice [27], thus conﬁrming the important
role of AMPK in mediating the vasodilatory effect of resveratrol.
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endothelium-dependent vasodilatory effects of resveratrol, resveratrol
has been shown to enhance NOS activity by increasing tetrahydro-
biopterin (BH4) levels, a cofactor necessary for proper function of NOS
[55]. The endothelium-dependent vasodilatory effect of resveratrol
has also been attributed to the anti-oxidant properties of resveratrol
[41,56]. Resveratrol has both intrinsic anti-oxidant properties, as well
as anti-oxidant effects secondary to up-regulation of endogenous
anti-oxidant enzymes [57]. Of importance, resveratrol has been shown
to attenuate vascular oxidative stress by up-regulation of superox-
ide dismutase (SOD) through a nuclear factor erythroid-2 related
factor-2 (NRF2)-dependent mechanism [55]. Interestingly, there are
multiple cross-talks between anti-oxidant enzymes and the SIRT1 and
AMPK-dependent pathways. Indeed, resveratrol can reduce oxidative
stress in endothelial cells via increased endothelial SIRT1 expres-
sion [58]. In addition, SIRT1 has been shown to mediate the activating
effect of moderate dose of resveratrol on AMPK [59]. As such, it appears
as though all of these pathways can signal one another to mediate the
effects of resveratrol during different conditions.
In addition to stimulating endothelium-dependent vasodilation, res-
veratrol has also been shown to have endothelium-independent
vasodilatory mechanisms. In human internal mammary artery rings
with denuded endothelium, resveratrol has been shown to cause a
concentration-dependent relaxation through a K+ channel-mediated
mechanism [60]. Cao et al. demonstrated that the BP lowering effect of
resveratrol may be attributed to the AMPK-mediated inhibition of
vascular smooth muscle cell (VSMC) contractility through the suppres-
sion of myosin phosphatase-targeting subunit 1 (MYPT1)/myosin light
chain (MLC) phosphorylation [27]. Furthermore, resveratrol reduces
the expression of vasoconstrictor molecules such as Ang II and
endothelin (ET)-1 [29,61]. Resveratrol inhibits strain-induced ET-1
gene expression by interferingwith the ERK1/2 pathway through atten-
uation of ROS formation [62]. Since the vascular tone depends on cyto-
plasmic Ca2+ concentration [Ca2+]i in VSMC, effects of resveratrol on
Ca2+ handling can contribute to its vasodilatory effects [63]. Indeed,
resveratrol has been shown to reduce both vasopressin- and Ang
II-induced increases in [Ca2+]i in A7r5 aortic smooth muscle cells
[64]. Similarly, resveratrol has been shown to attenuate both extra-
cellular Ca2+ inﬂux by inhibiting L-type Ca2+ channels, and intra-
cellular Ca2+ release by inhibiting inositol triphosphate (IP3)-gated
Ca2+ channels, leading to vasorelaxation of rat abdominal aortic rings
[65]. In addition to the direct effects on vascular cells, a central effect
of resveratrol has also been demonstrated. For instance, resveratrol mi-
croinjection into the rostral ventrolateralmedulla lowered BP and heart
rate by decreasing the sympathetic vasomotor tone [66], whichmay be
mediated through NO synthesis and a decrease in Ca2+ inﬂux [66]. Res-
veratrol has also been shown to activate AMPK in the nucleus tractus
solitarii (NTS) in the brainstem of fructose-fed rats [67], and it has
been proposed that this activation lowers BP through decreasing ROS
generation, enhancing Akt–nNOS pathway activity, and up-regulating
SOD2 levels in the NTS [67].
In addition to systemic hypertension, resveratrol has also been
shown in some animal studies to protect against and/or reverse pulmo-
nary hypertension [68]. In models of monocrotaline-induced pulmo-
nary hypertension, resveratrol has been shown to prevent the increase
in right-ventricular systolic pressure and right ventricular hypertrophy
[69,70]. In this model, resveratrol improved endothelial function, atten-
uated inﬂammation and oxidative stress, and inhibited proliferation of
pulmonary artery smooth muscle cells [70]. In addition, resveratrol
has also been shown to reverse established pulmonary hypertension
when it was administered 28 days after the monocrotaline injection
[71,72]. In a model of pulmonary thromboembolism-induced pulmo-
nary hypertension, two doses of resveratrol (10 mg/kg; IP) signiﬁcantly
reduced mean pulmonary artery pressure through down-regulation of
monocyte chemo-attractant protein-1 (MCP-1), and P-p38 mitogen-
activated protein kinase (MAPK) [73]. Together, these studies showthat resveratrol has multiple beneﬁcial effects on the vasculature and
may hold promise for the treatment and/or prevention of systemic hy-
pertension as well as pulmonary hypertension.
2.2. Clinical studies
Compared to the amount of preclinical data about the effects of
resveratrol on BP regulation, there is much less information available
from studies that investigate the effects of resveratrol on BP in
humans. A recent meta-analysis of 6 randomized controlled trials in-
vestigated the effect of resveratrol on BP and reported that high
doses of resveratrol (≥150 mg/day) signiﬁcantly reduced systolic
BP [74–76], while lower doses had no effect on BP [77–79]. Although
both high doses and low doses had no effect on diastolic BP, it has
been suggested that systolic BP is a more important CVD risk factor
than diastolic BP [80]. However, it is important to mention that this
meta-analysis included a study that used resveratrol-rich extract in-
stead of pure resveratrol [77], thus potentially confounding the con-
clusions. Since the reduction in systolic BP in two of these studies
occurred in association with better glycemic control in the resvera-
trol groups [74,75], and the BP lowering effect of resveratrol was ac-
companied by general improvement of several metabolic parameters
in another study [76], it is not known whether the anti-hypertensive
effect of resveratrol is due to a direct vasodilatory effect, or second-
ary to the correction of these metabolic perturbations. Nevertheless,
the effects observed in humans re-capitulate most of the animal
studies that showed the same dose-dependent effect of resveratrol
on systolic BP (Table 1).
Since the aforementioned studies investigated the BP lowering effect
of resveratrol in healthy subjects or in normotensive patients with met-
abolic conditions, it was not surprising that resveratrol did not exert a
substantial BP lowering effect. In agreement with this, in healthy non-
obese individuals, resveratrol along with 9 other dietary supplements
did not affect arterial stiffness, endothelial function, biomarkers of in-
ﬂammation and oxidative stress, and cardiometabolic risk factors [81].
However, the systolic and diastolic BPs of the participants of this study
were already optimum, average of 109 and 66 mm Hg, respectively
[81]. Therefore, it is likely that the BP lowering effect of resveratrol
would be more pronounced if resveratrol is administered to hyperten-
sive individuals. Consistent with this notion, resveratrol has been
shown to enhance Ach-evoked vasorelaxation in blood vessels from pa-
tients with hypertension and dyslipidemia, but not in vessels from non-
hypertensive non-dyslipidemic subjects [55]. Although resveratrol sup-
plementation in healthy obese adults and in patientswithmetabolic syn-
drome did not affect systolic or diastolic BP values in some studies, it
caused a signiﬁcant improvement of ﬂow-mediated dilatation in these
subjects [79,82], suggesting that resveratrol may prevent the develop-
ment of hypertension in these subjects. However, this is only specula-
tion as the duration of these clinical trials was too short to determine
the long-term consequence of the intervention. Unfortunately, there is
no clinical trial that we are aware of that investigated the BP lowering
effect of resveratrol in hypertensive patients,which should be the target
population for this effect (Table 7).
3. Atherosclerosis
Atherosclerosis can contribute to multiple CVDs through luminal
narrowing and/or thrombus formation that obstruct blood ﬂow to the
heart (CAD), brain (ischemic stroke), or lower extremities (peripheral
vascular diseases) [83]. The generation of atherosclerotic plaques is usu-
ally initiated by the concentration-dependent transport of low density
lipoproteins (LDL) into the arterial wall, followed by modiﬁcation of
these lipids by oxidation and/or inﬂammation, invasion ofmacrophages
and their transformation to foam cells, inﬁltration of smooth muscle
cells, and production of ﬁbrin and extracellular matrix [84]. Interesting-
ly, all of these detrimental processes can be attenuated by resveratrol
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of traditional lipid-lowering medications which work mainly by lower-
ing the cholesterol and/or triglycerides levels [86].
3.1. Preclinical studies
Several animal studies have shown that resveratrol can lower
plasma levels of total and LDL cholesterol, as well as triglycerides, and
increase the level of HDL cholesterol (Table 2) [87–91]. Of clinical signif-
icance, resveratrol potentiated the protective effect of pravastatin, a
commonly prescribed anti-hypercholesterolemicmedication, when ad-
ministered together tomale Sprague–Dawley rats fed a high cholesterol
diet [90]. The main proposed mechanism of resveratrol cholesterol-
lowering effect is the down-regulation of the hepatic 3-hydroxy
3-methylglutaryl coenzyme A (HMG-CoA) reductase enzyme, a
key enzyme in cholesterol biosynthesis [88–90]. Another proposed
mechanism for the cholesterol-lowering effect of resveratrol is via in-
creased liver expression of cholesterol 7α-hydroxylase (CYP7A1)
which leads to increased bile acid synthesis and secretion, thus lower-
ing the plasma level of total and LDL cholesterol [92]. Moreover, resver-
atrol has also been shown to increase the expression of LDL receptors in
hepatocytes in vitro, thus increasing the hepatic uptake of LDL, through
an AMPK independentmechanism [93]. Although these studies suggest
that the lipid lowering effects of resveratrol likely contribute to
preventing atherosclerosis, some other studies have demonstrated an
anti-atherosclerotic effect of resveratrol without lowering the lipid
plasma levels [94–96], suggesting that resveratrol may also interfere
with other steps in the pathogenesis of atherosclerosis.
The second step in the process of atherosclerosis is LDL oxidation,
which promotes macrophage migration into the vessel wall. Following
this, macrophages take up oxidized LDL and are transformed into
foam cells that initiate the atherosclerotic lesion [97]. Resveratrol has
been shown to reduce oxidized LDL cholesterol, an effect that was
attributed to the anti-oxidant effect of resveratrol [96,98]. Indeed,
resveratrol has both intrinsic anti-oxidant properties in addition to its
ability to induce several endogenous anti-oxidant enzymes such as
SOD and NADPH quinine-oxidoreductase [99,100]. Resveratrol has
also been shown to impede the cholesterol accumulation in human
macrophages by mechanisms that involve increased expression ofTable 2
Effect of resveratrol on plasma lipids and atherosclerosis.
Model Resveratrol dose
High fat diet-fed male Wistar rats 1 mg/kg body weight in drinking wa
Atherogenic diet-fed C57BL6/J mice 0.0125% diet
High fat diet-fed male Syrian Golden Hamster 0.025% diet
ApoE-deﬁcient male mice 0.02 and 0.06% diet
2% high cholesterol diet-fed male Sprague–Dawley rats 20 mg/kg/day — orally
High cholesterol diet-fed male New Zealand rabbits 3 mg/kg/day — orally
High cholesterol diet-fed male New Zealand rabbits 4 mg/kg/day — orally
Female CD rats 20 and 40 mg/kg/day IP
High cholesterol diet-fed New Zealand rabbits 0.6 mg/kg/day for 5 days, then 1 mg/kg/
from day 6 to 60 (dissolved in ethanol,
injected IP)
High cholesterol diet-fed male rabbits 2 mg/kg/day in diet
High cholesterol diet-fed Wistar rats 20 mg/kg/day IP
High fat diet-fed C57Bl mice 200 mg/kg diet/day
High Fructose corn syrup-fed male Wistar rats 500 mg/kg diet
Early weaning rat offspring 30 mg/kg/day by oral gavage
High fructose corn syrup 50 mg/L in drinking waterreverse cholesterol transport proteins such as peroxisome proliferator-
activated receptor-γ (PPARγ), liver X receptor-α (LXRα), 27-
hydroxylase, and ATP-binding cassette transporter A1 (ABCA1) [98,
101]. Since inﬂammation is essential for the progression of atheroscle-
rosis, the anti-atherosclerotic effects of resveratrol can also be explained
by its anti-inﬂammatory properties [102]. Consistent with this, resvera-
trol treatment has been shown to inhibit interleukin (IL)-6 and IL-8 pro-
duction in human coronary artery smooth muscle cells [103], inhibit IL-
6 release by stimulatedmacrophages [104], and reduce the serum levels
of IL-1β, IL-6, and tumor necrosis factor-α (TNFα) in an atherosclerotic
rabbit model [105]. Resveratrol has also been shown to inhibit TNFα-
mediated adhesion of neutrophils and monocytes to endothelial cells
by reducing the expression of the intercellular adhesion molecule-1
(ICAM-1) and vascular cell adhesionmolecule-1 (VCAM-1) through nu-
clear factor-kappaB (NF-κB) inhibition [106,107]. Similarly, resveratrol
has been shown to reduce hyperglycemia-induced ICAM-1 expression
in endothelial cells via the p38 MAPK pathway [108]. In cultured endo-
thelial cells, the anti-inﬂammatory effects of resveratrol have been at-
tributed to inhibition of cyclo-oxygenase-2 (COX-2) and matrix
metalloproteinase-9 (MMP-9) [109,110].
In agreement with the known cross talk between inﬂammation and
oxidative stress, resveratrol pre-treatment strongly suppressed LPS-
induced foam cell formation through the inhibition of LPS-induced
NADPH oxidase-1 and ROS generation [111]. Similarly, resveratrol has
been shown to protect endothelial cells by inhibiting NADPH-oxidase
and attenuating ROS production [112,113]. Resveratrol also counteracts
7-oxo-cholesterol-induced inﬂammation and NF-κB activation in
human macrophages, suggesting an important role of resveratrol to
protect against the pro-atherogenic effect of oxysterols [114]. Further-
more, resveratrol has been shown to prevent the age-associated pro-
inﬂammatory phenotype in vascular smooth muscle cells of a non-
human primate, suggesting a vasoprotective effect of resveratrol in an-
imal models of aging [115]. The vascular protective effect of resveratrol
can also be attributed to the increase of serum adiponectin level [116],
which is known to protect the vasculature through a number of mech-
anisms [117]. Therefore, the anti-oxidant and the anti-inﬂammatory
properties of resveratrol may also mediate its anti-atherogenic effect
through inhibiting LDL oxidation, macrophage migration, and macro-
phage transformation into foam cells.Duration Effect Ref
ter 45 days Reduced oxidized LDL, no effect on Total Cholesterol, LDL,
HDL, or triglycerides
[96]
8 weeks Reduced level of plasma cholesterol and triglycerides [87]
8 weeks Reduced level of plasma cholesterol and triglycerides [88]
20 weeks Reduced total cholesterol and LDL [89]
2 weeks Reduced plasma total cholesterol, triglycerides, LDL levels.
Improved functional recovery after ex-vivo I/R injury.
Increased capillary density after in vivo LAD occlusion
for one week
[90]
12 weeks No change in lipid proﬁle. Reduced atherosclerotic
plaques. Improved ﬂow-mediated dilation
[95]
4 weeks No change in lipid proﬁle. Signiﬁcant reduction in
ADP-induced platelet aggregation
[318]
21 days No change in lipid proﬁle [319]
day 60 days No change in lipid proﬁle. Increased atherosclerotic lesions [320]
24 days No change in lipid proﬁle Signiﬁcant anti-atherosclerotic
and anti-inﬂammatory effect
[94]
20 days Decreased LDL, VLDL, triglycerides; increased HDL; decreased
markers
of platelet activation
[91]
8 weeks Decreased LDL and total Cholesterol; increased HDL;
no effect on triglycerides
[92]
12 weeks Decreased triglycerides, and total cholesterol [321]
30 days Reduced SBP, DBP, triglycerides, and LDL [314]
10 weeks Reduced SBP, triglycerides, and total cholesterol [35]
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sclerotic plaque where they proliferate and secrete an extracellular ma-
trix to form a capped ﬁbrous lesion [85]. Importantly, resveratrol has
been shown to suppress both VSMC migration [118–120], and prolifer-
ation [121–124]. In addition, resveratrol has been shown to inhibit
neointimal cell proliferation after vascular injury in an eNOS-
dependent mechanism [125]. VSMCmineralization is another common
feature of atherosclerosis which can also be reduced by resveratrol
through opposing apoptosis and oxidative stress [83]. However, the ef-
fect of resveratrol on VSMC differentiation is controversial. While res-
veratrol has been demonstrated to induce VSMC differentiation
through SIRT1 and AMPK-dependent pathways [126], resveratrol has
also been shown to induce VSMC dedifferentiation by regulating
myocardin and serum response factor (SRF)-mediated VSMC gene ex-
pression [127]. Therefore, resveratrol canprotect against atherosclerosis
through its anti-proliferative, anti-migratory, and anti-mineralizing ef-
fects on the VSMCs. However, further research is needed to elucidate
the effect of resveratrol on VSMC differentiation and help explain how
this may contribute to its anti-atherogenic effect.
In humans, after decades of slow progression, the atherosclerotic
plaques may suddenly rupture causing life-threatening coronary throm-
bosis [83]. Interestingly, several studies have shown that resveratrol can
also inhibit important steps in the process of thrombogenesis [85]. Olas
et al. have shown that resveratrol decreases platelet adhesion to both col-
lagen and ﬁbrinogen after activation with LPS or thrombin [128]. There
are several proposedmechanisms to explain the anti-platelet effect of res-
veratrol. For instance, resveratrol has been shown to inhibit collagen-
induced platelet activation via inhibition of the p38 MAPK and activation
of theNO/cGMPpathways [129]. In hypercholesterolemic rats, resveratrol
(20 mg/kg/day) for 20 days inhibited the expression of severalmarkers of
platelet activation [91]. It has also been shown that resveratrol inhibits
platelet activation through the inhibition of protein kinase C (PKC)
[130], and phospholipase C beta [131]. In addition, resveratrol has been
shown to simultaneously inhibit platelet aggregation and induce platelet
apoptosis [132]. Conversely, although a mixture of grape polyphenolic
compounds inhibited platelet activation, resveratrol alone was unable to
inhibit platelet activation in one study [133]. However, resveratrol in-
hibits epinephrine- and collagen-induced aggregation of platelets
from aspirin-resistant patients [134], suggesting that resveratrol
may be a second-line anti-platelet in these aspirin-resistant patients.
This is particularly important from a clinical perspective since aspirin
remains the most clinically used anti-platelet medication and up to
20% of serious vascular events in high risk vascular patients can be
attributed to aspirin-resistance [135].
3.2. Clinical studies
In contrast to the promising results from animal studies, clinical trials
that investigated the effect of resveratrol on plasma lipid proﬁle in human
subjects have not been as clear (Table 7). For instance, in patients with
type 2 diabetes, a daily resveratrol dose of 250–1000 mg caused a signif-
icant reduction in LDL-cholesterol in two different studies [74,75]. Simi-
larly, there was a signiﬁcant reduction in plasma triglyceride levels in
healthy obese men and healthy adult smokers treated with resveratrol
150 mg/day and 500 mg/day, respectively [76,136]. In another study in
patients treated with statins and at high risk of CVDs, daily ingestion of
350 mg resveratrol-enriched grape extract containing 8 mg resveratrol
for 6 months caused a 20% reduction of oxidized LDL cholesterol but
only a modest 4.5% reduction in LDL cholesterol [137], suggesting that
the anti-oxidant effect of resveratrol may be more important than
its LDL cholesterol-lowering effect. Since a mixture of polyphenolic
compounds was used in this study, this effect may be attributed to
the synergistic effect between resveratrol and the other polypheno-
lic compounds, rather than due to resveratrol alone.
In contrast to these aforementioned studies, resveratrol had no
effect on lipid proﬁle in several other studies [78,79,82,138,139]. Inaddition, a meta-analysis of 7 clinical trials concluded that resveratrol
lacks a signiﬁcant effect on plasma lipid concentrations [140]. Neverthe-
less, there were several limitations mentioned in this meta-analysis
including the small size and heterogenecity of the study populations,
heterogeneous study designs, resveratrol dose, and duration of resvera-
trol supplementation [140]. In addition to these limitations, the meta-
analysis included two studies that used resveratrol-rich extracts instead
of pure resveratrol [137,141], again, potentially confounding the conclu-
sions. Therefore, the anti-atherosclerotic effect of resveratrol still needs
to be conﬁrmed by large long-term, well-controlled clinical trials that
assess the effect of resveratrol on all the aforementioned steps in the
atherosclerotic process, not only the plasma lipid proﬁle.
4. Stroke
The anti-atherosclerotic effects of resveratrol along with improving
endothelial function have also been attributed to the protective effect of
resveratrol against ischemic stroke [142]. As early as 2001, resveratrol
has been shown to reduce the infarct size in a rat model of focal cerebral
ischemia [143]. Although themechanism of this protective effect was not
thoroughly investigated, the authors attributed it to the anti-platelet,
vasodilatory, and anti-oxidant effects of resveratrol [143]. In another ani-
malmodel of recurrent ischemic stroke, resveratrol has been shown to re-
duce the extent of brain damage, preserve blood brain barrier function,
reduce inﬂammation, and protect the endothelial cells [142]. In this in-
stance, the authors suggest that the endothelial protective effect of resver-
atrol is, at least in part, SIRT1 dependent, but not NO-dependent [142].
Another in vitro study has shown that resveratrol promotes angiogenesis
in cerebral endothelial cells by activation of PI3K/Akt and MAPK/ERK
pathways leading to up-regulation of endothelial NOS and increased NO
synthesis [144]. Resveratrol also prevents diabetes-induced impairment
of eNOS-dependent vasorelaxation in cerebral arterioles, suggesting an
important therapeutic potential of resveratrol in treating cerebrovascular
dysfunction in diabetic patients [145]. Several other studies have attrib-
uted the protective effects of resveratrol from stroke to its neuroprotec-
tive effects [145–150], which have been reviewed previously [151].
Although there is nohuman clinical trial that investigated the protective
effects of resveratrol in stroke patients, a single dose of resveratrol has
been shown to increase the cerebral blood ﬂow during a performance
task in healthy adult subjects [152,153].
5. Myocardial ischemia and ischemia–reperfusion injury
Approximately 15.4 million Americans have coronary heart disease,
whichmakes upmore than half of all cardiovascular incidents in people
under the age of 75 [2]. According to theWHO, ~7.3 million people died
in 2008 due to ischemic heart disease [1]. Myocardial ischemia is caused
by an occlusion of one or more of the coronary arteries that results in a
decrease in oxygen supply to the myocardium. If the ischemic period
lasts for a prolonged period of time then cardiomyocyte death begins
and the ischemic episode causes a myocardial infarction (MI) [154].
The prevalence for MI among adults in the United States is 4.2% and
an estimated 620,000 Americans will experience a new coronary attack
this year [2]. As resveratrol has been shown to protect against ische-
mic damage and ischemia–reperfusion injury in a variety of non-
cardiac tissues [142,143,155,156], it is not surprising to ﬁnd that res-
veratrol has similar protective effects in the myocardium. Indeed,
resveratrol has been shown to protect against myocardial ischemia
by inhibiting platelet aggregation, preconditioning muscle tissue to
ischemia–reperfusion, and potentially regenerating tissue in the in-
farcted region [157].
5.1. Preclinical studies
There have been a number of studies investigating the effects of
resveratrol in the ischemicmyocardium, either examining its protective
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ischemia and infarction (Table 3). For instance, pretreatment with
resveratrol has been shown to protect against myocardial ischemia–re-
perfusion injury [90,158–164]. In rats with their left main coronary
artery ligated [160], preconditioning with resveratrol (1 mg/kg IP) for
60min prior to occlusion had signiﬁcant beneﬁts following reperfusion,
including a decreased severity of arrhythmia as well as a dramatically
reduced infarct size [160]. In another study, 10 μM resveratrol delivered
via transjugular injection 15 min prior to occlusion in rats restored sys-
tolic pressure and decreased the infarct size following reperfusion [163].
Moreover, resveratrol administration (5 mg/kg IP) to mice 24 h prior to
occlusion decreased infarct size following ischemia–reperfusion [164].
In a hypercholesterolemic rat model, resveratrol (20 mg/kg/day) pre-
treatment for twoweekswas also found to reduce infarct size in isolated
hearts following ischemia–reperfusion or in rats that had their left
descending coronary artery ligated in vivo [90]. Together, these results
highlight the ability of resveratrol to precondition the myocardium to
protect it from ischemia–reperfusion injury.
As mentioned, severe and prolonged myocardial ischemia results in
cell death and infarction. In addition to the beneﬁcial nature of resvera-
trol in ischemia–reperfusion, resveratrol has been proven to be beneﬁ-
cial inmodels of permanent ischemia. For example, resveratrol has been
found to be cardioprotective when given prior to left anterior descend-
ing (LAD) coronary artery ligation-induced infarction [158,159,161].
Speciﬁcally, pretreatment with resveratrol (1 mg/kg/day) for two
weeks reduced infarct size and improved cardiac function as early as
4 days following the MI [161]. Resveratrol pretreatment (5 mg/kg/
day) [158] or (10 mg/kg/day) [159] for one week prior to LAD ligationTable 3
Effect of resveratrol on myocardial ischemia and ischemia–reperfusion injury.
Animal model Resveratrol dose D
Rats with left coronary artery temporary
ligated and reperfused
0.5 mg/kg IP 6
o
Rats with left coronary artery temporary
ligated and reperfused
1 mg/kg/day IP 6
o
Rats with left coronary artery temporary
ligated and reperfused
10 μM IV 1
o
Mice with left coronary artery temporary
ligated and reperfused
5 mg/kg IP 2
o
Rats with left coronary artery permanently
ligated
20 mg/kg/day by oral gavage 3
Rats with left coronary artery permanently
ligated
10 mg/kg/day by oral gavage 4
Rats with left coronary artery permanently
ligated
1 mg/kg/day (8 mg/mL in drinking water) 1
Rats with left coronary artery permanently
ligated
5 mg/kg/day by oral gavage 4
Yorkshire miniswine with an ameroid
constrictor
100 mg/kg/day in diet 1
Rats with left coronary artery permanently
ligated
2.5 mg/kg/day by oral gavage 1
Rats with left coronary artery permanently
ligated
17 mg/kg/day in diet 1
Rats with left coronary artery permanently
ligated
0.1 mg/kg/day IP 4
Rats with left coronary artery permanently
ligated
1 mg/kg/day IP 4
Mice with left coronary artery permanently
ligated
20 mg/kg/day IP 6
Mice with left coronary artery permanently
ligated
5 mg/kg/day by osmotic pump 2
Mice with left coronary artery permanently
ligated
50 mg/kg/day by osmotic pump 2
Rats with left coronary artery permanently
ligated
5, 15, 45 mg/kg IV 1
toand continued for an additional threeweeks also increased survival, im-
proved contractile function and decreased infarct size [158,159]. Addi-
tionally, resveratrol treatment suppressed ventricular arrhythmias and
decreased cardiac hypertrophy [158]. Furthermore, in a porcine model
of ischemia, Yorkshire mini-swine treated with resveratrol (100 mg/
kg/day) for four weeks prior to the introduction of ischemia with an
ameroid constrictor (a device that gradually occludes blood ﬂow) and
seven weeks post surgery had improved vascular function [162]. How-
ever, in contrast to the previous beneﬁcial studies, Burstein et al. did not
observe the sameprominent protective role of resveratrol in a ratmodel
of MI [165]. In this instance, the rats were fed resveratrol (17 mg/kg/
day) for 13 weeks, one week prior to artery ligation and 12 weeks fol-
lowing the surgery. Although, resveratrol did not improve cardiac func-
tion under basal conditions, it did improve cardiac performance under
pharmacological stress testing with dobutamine [165]. The reasons for
the lack of a pronounced cardioprotective effect of resveratrol following
the infarct are currently unknown. Indeed, since the dose and duration
of resveratrol in the latter study exceed those in the other rodent stud-
ies, it is difﬁcult to say why they did not see the same beneﬁcial effects
as otherwise reported. One potential explanation is that the infarct size
varied between the studies. For example, in the studywhere resveratrol
was found to reduce infarct size, infarcts were ~50% (expressed as a
fraction of LV area) [158], whereas in the study where no change in in-
farct size was observed, infarct size was signiﬁcantly smaller (7%-
expressed as a fraction of heart weight). Thus, it is possible that the
cardioprotective effect of resveratrol is only evident with larger infarcts
[165]. Another explanation is that resveratrol is thought to be less
cardioprotective at higher doses in rodents. In rats fed 2.5 mg/kg/dayuration Effect on infarct size, cardiac function and survival Ref
0 min prior to
cclusion
BP and heart rate unaffected, no reduction in infarct size,
no reduction in arrhythmia, improved survival
[160]
0 min prior to
cclusion
BP and heart rate unaffected, reduced infarct size, reduced
incidence of arrhythmia, and improved survival
[160]
5 min prior to
cclusion
Reduced infarction and improved cardiac function [163]
4 h prior to
cclusion
Reduced infarct size [164]
weeks Reduced infarct size, increased capillary density,
and improved cardiac function
[90]
weeks Reduced infarct size, improved contractile function,
and improved survival
[159]
8 days Reduced infarct size and improved cardiac function [161]
weeks Prevented hypertrophic remodeling, reduced
infarct size, reduced incidence of ventricular
arrhythmias, and improved survival
[158]
1 weeks Improved perfusion, preserved vessel formation,
decreased wall motion abnormalities, and
improved cardiac function
[162]
6 weeks Improved cardiac function and survival [169]
3 weeks No change in infarct size, no effect on cardiac
function, no improvement on cardiac remodeling,
and no change in survival
[165]
weeks No decrease in infarct size, no improvement in
cardiac function, and no difference in survival
[167]
weeks Reduction of infarct size, improved cardiac function,
and no difference in survival
[167]
weeks Decreased hypertrophy, reduced infarct size,
improved cardiac function, and improved survival
[168]
weeks No change in cardiac hypertrophy, infarct size,
or cardiac function
[171]
weeks Reversed cardiac hypertrophy, reduced infarct size,
and improved cardiac function
[171]
0 min prior
occlusion
Dose-dependent reduction in the duration of
arrhythmia, arrhythmia score, incidence of ventricular
tachycardia, and mortality
[284]
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sion injury, whereas higher doses (25 mg/kg/day and 100 mg/kg/day)
did not [166].
The ability of resveratrol to protect the heart from ischemia, when
administered prior to the ischemic episode, is well established. Perhaps
of even more clinical relevance, however, is that resveratrol also
prevents cardiac damage when delivered after the insult. For instance,
it has been shown that left ventricular systolic/diastolic function
improved and infarct size was reduced in rats that received a daily
administration of resveratrol 1 mg/kg for four weeks post-MI [167]. In
addition, Xuan et al. performed left coronary artery ligation on mice
and found that resveratrol (20 mg/kg/day for 42 days) decreased cardi-
ac remodeling and increased survival following the MI [168]. Similar
positive results were observed in rats treated with 2.5 mg/kg/day res-
veratrol for 16 weeks post-MI [169]. In this latter study, resveratrol
treated rats had improved cardiac function, decreased mortality, and
decreased B-type natriuretic peptide (BNP) serum levels, demonstrat-
ing that resveratrol protected against the development of MI-induced
heart failure [170]. Finally, a two-week treatment with resveratrol
(50 mg/kg/day by osmotic pump) commenced four weeks following
an MI in mice improved cardiac performance and morphology [171].
Taken together, it appears that resveratrol may be effective at
preventing ischemic damage and infarct expansion following MI.
In addition to the cardioprotective role of resveratrol, it has also
been shown to protect against ischemia–reperfusion injury in other
organs as well. Indeed, resveratrol has been shown to protect against
ischemia–reperfusion injury in skeletal muscle in an animal model of
hind limb ischemia [172,173]. Similarly, resveratrol has also been
shown to protect against ischemia–reperfusion injury in ovaries of
female rats [155], testes of male rats [156], visceral organs [174], and
kidneys [175]. Although the authors of the previous studies have attrib-
uted the protective effects of resveratrol to its anti-oxidant and
cytoprotective effects in the target organs [155,156,172,173], these pro-
tective effects can also be attributed to the well-documented vascular
protective effects of resveratrol.
The ability of resveratrol to protect from myocardial ischemic dam-
age and/or ischemia–reperfusion injury is complex and involves nu-
merous mechanisms (Fig. 2). However, a primary mediator appears to
be the increased production of the cardioprotective molecule, NO
[176]. NO is a potent vasodilator and is beneﬁcial in the ischemic myo-
cardium by promoting perfusion of the damaged tissue [50]. Indeed,
rats treated with resveratrol prior to ischemia–reperfusion were
found to have elevated levels of NO, when compared to rats treatedFig. 2. Proposed anti-ischemic mechanisms of resveratrol. Resveratrol confers its anti-
ischemic effects through activation of AMP-activated protein kinase (AMPK), endo-
thelial nitric oxide synthase (eNOS), and vascular endothelial growth factor (VEGF),
and inhibition of reactive oxygen species (ROS) and atherosclerosis.with vehicle [163]. In addition to increasing NO levels, pretreatment
with resveratrol has been shown to increase eNOS and nNOS protein
levels in the ischemic myocardium compared with the vehicle treated
animals [159,160]. This may help explain the mechanism of
resveratrol-mediated protection as independent studies have clearly
shown that deﬁciency of eNOS worsens myocardial ischemia–reperfu-
sion injury [177,178] and its overexpression is cardioprotective [179,
180]. The putative role of NO being a mediator of the cardioprotective
effects of resveratrol is also supported by the various studies that have
indicated an increase in phosphorylation of eNOS at serine 1177 in the
presence of resveratrol [25,90,162]. Furthermore, in rats treated with
L-NAME (an inhibitor of NOS), resveratrol-dependent recovery of cardi-
ac function was abrogated, suggesting a crucial role of NOS in the pro-
tective nature of resveratrol [160,181]. Overall, these ﬁndings suggest
that resveratrol is cardioprotective in part through the stimulation of
NO production and subsequent vasodilation.
In addition to promoting vasodilation, NO is a well-knownmediator
of angiogenesis [182], and therefore it seems likely that resveratrol may
also protect the heart from ischemic damage via this mechanism.While
this would only be applicable in chronic ischemia, a number of studies
have observed that pretreatment with resveratrol increases myocardial
capillary density following MI. In addition to NO stimulation [163] and
eNOS activation [25,90,162], resveratrol has also been shown to in-
crease expression of pro-angiogenic factors, such as vascular endothelial
growth factor (VEGF) and heme oxygenase-1 [90,159,161]. However,
another study demonstrated that although resveratrol seemed to im-
prove vascular function through increased expression of VEGF and
phosphorylation of eNOS, no increase in capillary density was observed
[162]. The authors of this latter study provided several explanations for
the differences in their study compared to other studies including:
7 weeks following implantation with an ameroid constrictor may not be
enough time to observe vessel formation, prolonged Akt activation may
inhibit angiogenesis [183], or the potential presence of angiogenic inhib-
itors not measured in their study, such as endostatin or angiostatin [162].
Finally, the high dose of resveratrol they used (100 mg/kg/day) may ex-
plain the lack of observed vessel growth, as resveratrol has been shown
to inhibit angiogenesis at 30 mg/kg/day or higher [184–187].
Resveratrol also likely protects the heart from ischemia–reperfusion
injury through the reduction in oxidative stress. As the myocardium is
reperfused following an acute ischemic episode, the tissue is damaged,
in part, by the generation of ROS [188]. Resveratrol has been shown to
reduce lipid-peroxidation [163,189], reduce the levels of superoxide
[46,190], and activate anti-oxidant defense mechanisms [161,189]. A
recent proteomics study on Yorkshire miniswine implanted with an
ameroid constrictor identiﬁed a number of differences in proteins
expressed in the animals pre-treated with resveratrol [191]. One of
the proteins that were overexpressed in the animals treated with res-
veratrol was the radical scavenging protein peroxiredoxin 2. Therefore,
it seems likely that resveratrol also protects the reperfused ischemic
heart by minimizing damage resulting from ROS.
In addition to the importance of vasodilation, reduced oxidative
stress, and vessel formation, the activation of AMPK and/or SIRT1by res-
veratrol to trigger autophagy in the cardiomyocyte has been identiﬁed
as a potential protective mechanism. In H9c2 cells, resveratrol was
found to reduce cell death induced by H2O2 through activation of
AMPK [190]. Furthermore, pretreatment of H9c2 cells with resveratrol
prior to anoxia/re-oxygenation, reduced cell death in an AMPK and
autophagy-dependent manner [166]. Resveratrol was also shown to
be protective in cardiomyocytes exposed to anoxia/reoxygenation
through inhibition of fractalkine (FKN) [168], which was shown to in-
hibit the resveratrol-enhancement of autophagy in cardiomyocytes
[168]. The roles of FKN and autophagy are important as it has been
shown that autophagy is beneﬁcial following MI due to a correction of
the myocardial energy imbalance [192].
In rats exposed to ischemia–reperfusion, low doses of resveratrol in-
duced autophagy and decreased apoptosis in the myocardium and
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function [166]. AMPK-dependent activation of autophagy was also cor-
related to the beneﬁcial effects of resveratrol in mouse hearts following
MI and inhibition of autophagyworsened cardiovascular function [171].
In addition to the role of AMPK, SIRT1 has been implicated in the ability
of resveratrol to promote autophagy. For instance, in aMImodel in rats,
resveratrol increased SIRT1 and AMPK expression, and in vitro studies
indicated that inhibition of SIRT1 decreased AMPK levels [169]. More-
over, in mice pretreated with resveratrol, a decrease in infarct size
coupled with an increase in deacetylated substrate (indicating SIRT1
activation) was observed following ischemia–reperfusion [164]. Addi-
tionally,mice pretreatedwith sirtinol (a SIRT1 inhibitor) almost entirely
abolished the beneﬁcial effects of resveratrol [164], and prevented
autophagy in vitro [193], which strongly supports the integral role of
SIRT1-activation in mediating some of the effects of resveratrol. Overall,
these studies show that resveratrol functions by a variety of mecha-
nisms to protect the heart from damage following ischemia, ischemia–
reperfusion, and myocardial infarction. The primary mechanisms
appear to involve a decrease in oxidative stress, and an increase in vaso-
dilation, angiogenesis, and autophagy.
5.2. Clinical studies
The effect of resveratrol in patients with ischemic heart disease has
been investigated in a few clinical trials. Oral administration of resvera-
trol, calcium fructoborate (CF), and their combination was shown to
improve several markers in patients with stable angina pectoris [194].
CF is a naturally occurring mixture of calcium, fructose and boron
found in fruits, vegetables, herbs and wine and may have its own anti-
inﬂammatory properties [195]. Furthermore, since CF has been shown
to stabilize resveratrol in the digestive tract [194], it may enhance the
effects of resveratrol. This study was randomized, double-blinded,
active-controlled and paralleledwith three groups. In total, 116 patients
were split into four groups: 29 patients in control group, 29 patients
receiving 20 mg/day resveratrol, 29 patients treated with 20 mg/day
resveratrol and 112 mg/day CF, and 29 patients receiving 112 mg/day
CF. The study was conducted for 60 days, throughout which time pa-
tients continued to receive normal therapy. Dramatic reductions in
high-sensitivity C-reactivity protein, a biomarker of inﬂammation and
the N-terminal prohormone of BNP (NT-proBNP), a biomarker of cardi-
ac dysfunction, were observed for all three groups, with the largest re-
ductions occurring in the CF group and the CF and resveratrol groups.
Lipid proﬁles (LDL and HDL cholesterols and triglycerides) were also
slightly improved across the treatment groups. Importantly the sub-
jects' quality of life (deﬁned by angina episodes/week,weekly nitroglyc-
erin consumption, and improvement in angina class) was also
dramatically improved across the treatment groups, with the largest
gains observed in the combined CF + resveratrol group. A limitation
of the study is that while the authors suggest that CF stabilizes, and
therefore improves the bioavailability of resveratrol, plasma levels
were notmeasured to conﬁrm this. Nevertheless, it seems that the com-
bination of resveratrol with CF had beneﬁcial effects and improved the
quality of life of patients with stable angina pectoris.
There has also been a clinical study focusing on the effects of
resveratrol in a grape extract on patients with CAD (stable angina or
acute coronary syndrome) [196]. This study was a three-arm parallel,
randomized, triple-blind, placebo-controlled trial that occurred over
the course of 1 year with patients with stable CAD receiving either pla-
cebo, a conventional grape extract (GE), or a grape extract containing
resveratrol (GE-resveratrol). In this case, the trial compared placebo
(25 patients) with grape extract (25 patients) and grape extract con-
taining resveratrol (25 patients). Patients received 350 mg/day (in
the GE-resveratrol, 8 mg resveratrol) for the ﬁrst six months of the
study and 700 mg/day (16 mg resveratrol) for the next 6 months.
The patients receiving GE-resveratrol had increased levels of the
anti-inﬂammatory adipokine, adiponectin, and a reduction in thethrombogenic plasminogen activator inhibitor type 1 (PAI-1), sug-
gesting that resveratrol may be cardioprotective, since increasing
adiponectin [197] and/or decreasing PAI-1 [198] has been proposed
to be a promising therapy for CAD. Moreover, there was a downreg-
ulation of pro-inﬂammatory genes expressed in peripheral blood
mononuclear cells (PBMCs) in the GE-resveratrol group. The athero-
genic lipid load decreased in both grape extract groups, demonstrat-
ing that there may be other beneﬁcial components in the grape
extract. Consistent with the previous clinical trial, these data point
toward the potential of resveratrol as a treatment of CAD.
There has also been a clinical study examining the effects of resver-
atrol treatment in patients whohave had anMI [199]. This double blind,
placebo controlled, randomized study included 40 Caucasian patients
(26 men and 14 women with a mean age of 66.3 years) studied over
the course of 3 months. The patients received either placebo or
10 mg/day resveratrol in conjunction with standard medication over
the course of the treatment. In patients treated with resveratrol, dia-
stolic function was signiﬁcantly improved with a modest increase in
systolic function, endothelial function was improved, red blood cell
deformability was increased, platelet aggregation was inhibited
(with increased sensitivity to aspirin), and LDL cholesterol levels
were decreased. Although it is unknown if there is a direct effect of
resveratrol on the cardiomyocytes in these patients, it seems at
least that resveratrol mediates its effects in this patient cohort via
improved vascular function and/or preventing negative conse-
quences associated with atherosclerosis. As such, this ﬁnding sug-
gests that resveratrol treatment of post-MI patients, when given in
conjunction with other prescribed therapeutic agents, may be a
promising approach to lessen the risk of secondary MI.
6. Cardiac hypertrophy and the pathogenesis of heart failure
Heart failure is a clinical syndrome that arises from a variety of
pathophysiologies including, hypertension, MI, and congenital car-
diomyopathies [200]. Heart failure can also be caused by diabetic
cardiomyopathy [201], chemotherapeutic agents [202,203], rheu-
matic valve disease, Chagas' disease, and endomyocardial valve dis-
ease [200]. Heart failure is deﬁned as the inability of the heart to
supply the body's organs and tissues with enough oxygen and nutri-
ents to meet its metabolic demands. The goals of treatment of heart
failure includes stabilizing the symptoms and reversing myocardial
dysfunction using common treatments such as beta-blockers,
diuretics, renin–angiotensin–aldosterone inhibitors, vasodilators,
and/or positive inotropes [204]. Despite these treatments, heart
failure remains a debilitating disease with a poor prognosis [200,
205]. In fact, in the United States, roughly 1 in 9 deaths is caused by
heart failure [2], demonstrating the clinical burden of this syndrome.
The natural response of a decrease in heart function is cardiac re-
modeling such that function can bemaintained. Thismyocardial remod-
eling involves numerous processes [206] including cardiac hypertrophy,
which is characterized by an increase in cardiomyocyte size [205]. In the
short-term, cardiac hypertrophy is compensatory but often progresses
to a maladaptive form of hypertrophy that eventually contributes to
poor contractile performance [205]. Indeed, the hypertrophied heart
consumes more energy and is stiffer than the healthy heart [205] and
the maladaptive hypertrophy ultimately impairs systolic and diastolic
function. These changes can contribute to the pathogenesis of heart fail-
ure and/or worsen existing heart failure [157]. Since pathological cardi-
ac hypertrophy leads to heart failure, the ability to prevent, arrest, or
even reverse this process may have important therapeutic potential
[205].
6.1. Preclinical studies
In order to screen for effective treatments of heart failure, a number
of animal models have been developed in an attempt to mimic the
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tigated in a number of these models including pressure-overload
[208–210], volume overload [210], SHRs [30,32], doxorubicin-induced
cardiotoxicity [202,203] (see Chemotherapy-induced cardiotoxicity
section), MI, ischemia–reperfusion injury [168,169,171], myocarditis
[211], and a TO-2 hamster model of heart failure [212] (Table 4).
Many studies using resveratrol in these models focus on the ability of
resveratrol to prevent cardiac hypertrophy and/or prevent cardiac
dysfunction leading to heart failure as opposed to testing resveratrol
as a heart failure treatment per se. Notwithstanding this fact, cardiac
hypertrophy and cardiac dysfunction are extremely important in the
pathogenesis of heart failure and these studies still have signiﬁcant
value.
Pathological stress, such as increased load on the heart or cardiomy-
opathies that alter the contractile function of the heart, typically leads to
cardiac hypertrophy [205]. As has been discussed, the ability to reduce
hypertension and reduce cardiac afterload also predictably prevents
cardiac hypertrophy [213]. Indeed, there have been a number of studies
that have indicated that resveratrol (either administered in pure form
or in a diet rich in resveratrol, such as in grape powder) is capable of
preventing and reversing cardiac hypertrophy caused by hypertension
(Table 4) [25,28,30,32,33,210,214,215]. While many of the hyperten-
sion studies suggested that the reduction in BP contribute to the im-
provement in cardiac hypertrophy, several other studies have
indicated that resveratrol can reduce cardiac hypertrophy even in the
absence of a decrease in BP. For instance, in the SHR, lowdoses of resver-
atrol (2.5 mg/kg/day) prevented cardiac hypertrophywithout reducing
BP [30,32]. Furthermore, resveratrol reduced cardiac hypertrophy in
surgical models of increased afterload [208–210], which are mechani-
cally conﬁned to elevated afterloads. Additionally, resveratrol has been
shown to prevent/treat heart failure inmodelswhere elevated afterload
is not the cause of hypertrophy, such as in the TO-2 hamster model of
heart failure [212], in the experimental model of autoimmune myocar-
ditis [211], in a number of rodent models of infarction [158,167–169,
171], and in isolated cardiomyocytes [216]. Together, these results
imply that resveratrol can prevent cardiac hypertrophy and dysfunction
through cardiomyocyte autonomous effects and not solely from a more
general mechanism of reduced BP [4,157].Table 4
Effect of resveratrol on cardiac hypertrophy/function.
Animal model Resveratrol dose
SHR 2.5 mg/kg/day by oral gavage
SHR 2.5 mg/kg/day by oral gavage
SHR 2.5 mg/kg/day by oral gavage
Rats with abdominal aortic banding-induced
pressure-overload
2.5 mg/kg/day by oral gavage
Rats with shunt induced volume-overload 2.5 mg/kg/day by oral gavage
Rats with shunt induced volume-overload 2.5 mg/kg/day by oral gavage
Rats with abdominal aortic banding-induced
pressure-overload
2.5 mg/kg/day by oral gavage
Rats with abdominal aortic banding-induced
pressure-overload
2.5 mg/kg/day by oral gavage
Partially nephrectomized rats 50 mg/kg/day by oral gavage
Fructose 10% in drinking water 10 mg/kg/day by oral gavage
Rats fed High fat diet 2.5 mg/kg/day by oral gavage
Mice with TAC-induced pressure-overload 10 mg/kg/day by oral gavage
TO-2 Hamsters prone to Heart Failure 145 mg/kg/day in diet
Experimental model of Autoimmune
Myocarditis in rats
50 mg/kg/day IP
Dahl-salt sensitive rats 18 mg/kg/day in dietThe ability of resveratrol to prevent cardiac hypertrophy and the de-
velopment of cardiac dysfunction has also been investigated in several
surgical models that initiate cardiac hypertrophy and can progress to
heart failure. Interestingly, resveratrol did not prevent cardiac dysfunc-
tion and remodeling in a volume-overload model of cardiac hypertro-
phy [210]. However, in an aortic-banded pressure-overload model of
hypertension, resveratrol (2.5 mg/kg/day) treatment prevented both
cardiac hypertrophy and cardiac dysfunction [210]. Recently, Gupta
et al. used transverse aortic constriction (TAC)-induced pressure-
overload model of cardiac hypertrophy in mice to study the effects of
resveratrol [209]. In that study, mice receiving 10 mg/kg/day resvera-
trol following the TAC surgery displayed signiﬁcantly reduced patholog-
ical cardiac remodeling and dysfunction as well as reduced oxidative
stress, inﬂammation,ﬁbrosis and apoptosis [209]. Moreover, resveratrol
treatment in an aortic-banded pressure-overload model of cardiac
hypertrophy in rats prevented and reversed hypertrophy [208,210].
Two weeks following surgery, rats were administered resveratrol
(2.5 mg/kg/day) for a total of four weeks. Following the treatment peri-
od, resveratrol improved contractile function and inhibited the develop-
ment of hypertrophy, speciﬁcally concentric remodeling [208]. The
ability of resveratrol to prevent cardiac hypertrophywas also investigat-
ed in the Dahl-salt sensitive (DSS) rat [217]. Rats were fed a high-salt
diet for 3 weeks and then treated with resveratrol (18 mg/kg/day
in diet) for an additional 8 weeks. Following the initial three-week
period prior to resveratrol treatment, BP and cardiac hypertrophy had
increased in the high salt treated rats. Interestingly, resveratrol treat-
ment increased survival rate, preserved myocardial function and
prevented endothelial dysfunction and muscle mitochondrial respira-
tion dysfunction, without decreasing BP [217]. These studies indicate
that resveratrol is able to restore cardiac structure and function follow-
ing the development of hypertrophy and therefore seems to be able to
reverse the early development of processes involved in the progression
to heart failure.
In many of the aforementioned studies, resveratrol was adminis-
tered prior to the development of heart failure. Indeed, there have
been a number of studies demonstrating that resveratrol can prevent
cardiac hypertrophy, improve cardiac function and impede the progres-
sion of heart failure following cardiac damage [158,167–169,171], andDuration Effect on cardiac hypertrophy/function Ref
2 weeks No effect on BP, reduced cardiac hypertrophy,
and improved cardiac function.
[30]
10 weeks No effect on BP, reduced cardiac hypertrophy,
and improved cardiac function
[32]
8 weeks Alleviated cardiac ﬁbrosis. No effect on BP,
diastolic function, or vascular remodeling
[31]
2 weeks Reduced cardiac hypertrophy, and improved
cardiac function
[208]
26 days No effect on cardiac hypertrophy and cardiac
dysfunction
[210]
14 days No effect on cardiac hypertrophy, and cardiac
dysfunction
[210]
26 days Reduced cardiac hypertrophy, and improved
cardiac function
[210]
14 days Reduced cardiac hypertrophy, and improved
cardiac function
[210]
4 weeks Reduced SBP and cardiac hypertrophy [29]
45 days Reduced SBP and cardiac hypertrophy [36]
6 weeks No effect on BP, improved cardiac function [315]
4 weeks Reduced cardiac hypertrophy, reduced remodeling,
and improved cardiac function
[209]
29 weeks Reduced cardiac hypertrophy, improved cardiac
function, and improved survival
[212]
2–3 weeks Reduced cardiac hypertrophy, reduced remodeling,
and improved cardiac function
[211]
8 weeks No effect on BP, reduced hypertrophy, improved
cardiac function and improved survival
[217]
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many of these previous studies are prevention studies and less work
has been published showing that resveratrol has beneﬁcial effects in an-
imals with established heart failure. Kanamori et al. addressed this by
examining the outcomes ofmicewith establishedMI-induced heart fail-
ure following treatmentwith resveratrol [171]. In that study,MI was in-
duced in mice via left coronary artery occlusion, and resveratrol
treatment was commenced 4 weeks after the surgery at a time when
left ventricle ejection fraction (LVEF) was signiﬁcantly reduced (~39%
versus ~74% in the sham animals) and animals displayed signs of
heart failure. Of importance, following 2 weeks of treatment with
resveratrol (50 mg/kg/day), LVEF improved from ~39% to ~47% likely
due to a decrease in the size of infarct and a reversal of the maladaptive
remodeling [171]. This study is particularly exciting as it suggests that
resveratrolmay be an effective treatment for heart failure by preventing
infarct expansion. However, whether this is relevant in humans with
established heart failure occurring from previous MIs where the scar
has typically already been formed is currently unknown. In addition, it
is unknown if resveratrol can be used as a treatment for heart failure
in non-ischemic models of heart failure.
There are several central mechanisms by which resveratrol imparts
its anti-hypertrophic and cardioprotective affects including: reduction
of oxidative stress, inhibition of protein synthesis, improved Ca2+-
cycling and inhibition of hypertrophic gene expression (Fig. 3). Oxida-
tive stress is an important trigger of heart failure [218] and is correlated
with an increase in severity of heart failure [188]. Oxidative stress has
also been shown to lead to cardiac hypertrophy [219]. One anti-
oxidant mechanism by which resveratrol may mediate its beneﬁcial
effects in heart failure pathogenesis is by increased expression of
SOD2. In a TO-2 hamster heart, resveratrol enhanced cardiac SOD2
expression in a SIRT1-dependent manner and reduced ROS [212]. Simi-
larly, SOD2 activity and levels of the ROS scavenger, glutathione, wereFig. 3. Proposedmechanisms of the protective effects of resveratrol against cardiac hyper-
trophy and heart failure. Resveratrol interferes with several processes implicated in the
pathophysiology of cardiac hypertrophy and heart failure. Resveratrol activates
AMP-activated protein kinase (AMPK) through the LKB1 pathway leading to inhibi-
tion of both protein synthesis and nuclear factor of activated T-cells (NFAT)-mediated
hypertrophic gene expression. Resveratrol also induces autophagy through both
AMPK and silent information regulator 1 (SIRT1) pathways. Lastly, resveratrol inhibits re-
active oxygen species (ROS) generation by activating the anti-oxidant enzyme superoxide
dismutase (SOD).increased by resveratrol in TACmicewhen compared to TACmice treat-
ed with vehicle [209]. On the other hand, in an MI model of cardiac hy-
pertrophy, the expression level of SOD2 was unaltered by resveratrol
[171], suggesting that SOD2 up-regulation may not be the main anti-
oxidant mechanism of resveratrol. Furthermore, although resveratrol
was found to reduce oxidative stress (in the form of thiobarbituric
acid reactive substances) in both pressure-overload and volume-
overload models of cardiac hypertrophy, it was only beneﬁcial in the
pressure-overload model of cardiac hypertrophy [210]. This implies
that the ability of resveratrol to inhibit hypertrophymay not be directly
mediated by its anti-oxidant effects. Another possibility is that oxidative
stressmay play a different role in the development of concentric hyper-
trophy (pressure-overload) versus eccentric hypertrophy (volume-
overload) [210]. Lastly, in addition to the anti-oxidant nature of resver-
atrol, its activation of eNOS may play an important role in slowing the
development of cardiac hypertrophy [208]. Indeed, Juric et al. found
that both eNOS and iNOS levels were reduced upon aortic banding,
and resveratrol partially restored their levels [208]. They hypothesized
that the anti-hypertrophic effect of resveratrol may in part be the result
of elevated NO, which has been shown to have both cardioprotective
and anti-hypertrophic properties [220]. Consistentwith this, resveratrol
was shown to increase serum NO levels in a partially nephrectomized
model of hypertrophy [29]. Together, these data suggest that resveratrol
may protect against cardiac hypertrophy through an anti-oxidant de-
pendent mechanism and/or NO production.
One of the hallmarks of cardiac hypertrophy is enhanced protein
synthesis [221]. Protein synthesis can be regulated by numerous pro-
teins including ones that control protein translation such as the eukary-
otic elongation factor-2 (eEF2) and p70S6 kinase (p70S6K) [222]. In
hypertrophic cardiomyocytes, resveratrol has been shown to inhibit
phenylephrine-induced cardiomyocyte hypertrophy by inhibiting
p70S6K and eEF2 through AMPK activation and Akt inhibition [216].
Likewise, resveratrol has also been shown to prevent hypertrophy
induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in H9c2 cells [223].
Although Akt plays a role in the development of cardiac hypertrophy
[224,225], since the anti-hypertrophic effects of resveratrol was not
lost in Akt1/2 null mouse embryonic ﬁbroblasts (MEFs) [216], it is
unlikely that Akt inhibition is the mechanism by which resveratrol pre-
vents cardiac hypertrophy. On the other hand, AMPK activation seems
to be essential for the anti-hypertrophic effects of resveratrol, since res-
veratrol was less effective at inhibiting hypertrophic signaling in AMPK
null MEFs [216]. Moreover, the anti-hypertrophic effect of resveratrol
was abolished by the AMPK inhibitor, compound C [226], and although
resveratrol treatment of SHR or Ang II infused mice activated AMPK, no
inhibition of Akt was observed [25,30,226]. Additionally, in a MI model
of heart failure progression, although resveratrol had a pronounced ac-
tivation of AMPK, no change in Akt phosphorylationwas observed [171]
. Together, these ﬁndings suggest that resveratrol inhibits cardiac hy-
pertrophy via AMPK-dependent pathways. Of importance, although
AMPK activation by resveratrol has been suggested to mediate its
anti-hypertrophic effects by reducing protein synthesis, activation of
AMPK also stimulates autophagy, which has been shown to also cause
a decrease in cardiac hypertrophy [192]. Since it has been shown that
resveratrol induces autophagy [168,171,193], it seems likely that this
too plays a role in resveratrol-mediated inhibition of cardiac hypertro-
phy and further research in this area is warranted.
Although resveratrol activates numerous molecular signaling path-
ways [227], the activation of AMPK appears to be an extremely impor-
tant mediator of many of the beneﬁcial effects of resveratrol in the
cardiomyocyte [4,228]. One potential mechanism by which resveratrol
leads to AMPK activation is via preventing 4-hydroxy-2-nonenal
(HNE)-mediated inhibition of LKB1 (the upstream kinase of AMPK)
[25,30]. HNE is an electrophilic lipid peroxidation by-product that is
formed during hypertrophy and inhibits LKB1 through the formation
of covalent adducts. LKB1 inhibition leads to a decrease in AMPK phos-
phorylation and an increase in cardiomyocyte hypertrophy [30].
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rescueAMPKactivity in cardiomyocytes, SHR, andAng II infusedmice [25,
30]. These data lend support to the argument that the anti-hypertrophic
effects of resveratrol are mediated through the activation of AMPK. Con-
sistent with the involvement of LKB1 in regulating cardiac hypertrophy,
SIRT1 has been shown to deacetylate and potentially activate LKB1 [59]
and may be another mechanism by which resveratrol activates AMPK.
Of importance to the regulation of cardiac hypertrophy and the
activation of AMPK, resveratrol-induced activation of SIRT1 is associated
with a reduction in cardiac hypertrophy [229]. For example, in the rat
model of myocarditis, resveratrol treatment caused a substantial
increase in SIRT1 expression levels [211]. Likewise, in an MI model of
heart failure, rats treated with resveratrol had improved cardiac
function and enhanced SIRT1 levels [169]. Furthermore, in a diabetic
model of cardiomyopathy in mice, resveratrol was shown to activate
SIRT1, promote autophagy, and prevent hypertrophy [193]. In the
same study, SIRT1 inhibition eliminated the resveratrol-mediated en-
hancement of autophagy in H2O2-treated H9c2 cells, suggesting that
SIRT1 plays an important role in the anti-hypertrophic effects of
resveratrol [193]. While it has been shown that at higher concentra-
tions, resveratrol is able to activate AMPK independent of SIRT1, the
beneﬁcial effects of resveratrol on mitochondrial function have been
attributed to a SIRT1-dependent mechanism [59]. However, the
involvement of SIRT1 as a mediator of the anti-hypertrophic effects of
resveratrol is not completely agreed upon. For instance, it has been pro-
posed that SIRT1 activation promotes cardiac hypertrophy through its
deacetylation and activation of Akt [230]. This is in agreement with
mouse models showing that high levels of SIRT1 expression results in
enhanced cardiomyocyte growth [231], and low SIRT1 expression pre-
vents hypertrophy [230], implying that SIRT1 activation by resveratrol
would lead to hypertrophy. As such, the role that resveratrol-
mediated SIRT1 activation plays in the development of cardiac hyper-
trophy has yet to be clearly established.
Since intracellular Ca2+ cycling determines contractility in normal
and failing hearts [232], the effects of resveratrol on Ca2+ handling
may be implicated in its protective effects in heart failure. Interestingly,
resveratrol has also been shown to improve cardiac function in diabetic
mice through increasing sarcoplasmic/endoplasmic reticulum calcium-
ATPase 2a (SERCA2a) expression in a SIRT1-dependent mechanism
[233]. Similarly, resveratrol restored SERCA2 promoter activity in a
SIRT1-dependent mechanism in primary cardiomyocytes cultured in
high glucose medium [233]. However, in a DSS rat model of heart fail-
ure, resveratrol treatment did not signiﬁcantly increase SERCA2 expres-
sion levels [217], suggesting that the effect of resveratrol on SERCA2 and
Ca2+ homeostasis may be model-dependent. Although the effect on
SERCA2 may still need to be clariﬁed, another mechanism that has
been proposed for AMPK activation by resveratrol is through activation
of calcium/calmodulin-dependent kinase kinase 2 (CamKK2) via an
increase in intracellular Ca2+ levels through phospholipase C and the
ryanodine receptor Ca2+-release channel [234]. Importantly, this
mechanism was identiﬁed in the skeletal-muscle derived C2C12 cell
line, and conﬁrmation of this mechanism in cardiomyocytes is still nec-
essary. Nevertheless, polydatin, a resveratrol glucoside, has been shown
to up-regulate the activity of ryanodine receptors and increase myoﬁla-
ment Ca2+ sensitivity resulting in an increase of cardiomyocyte con-
tractility [235]. Therefore, further research is needed to investigate
whether resveratrol can up-regulate the activity of ryanodine receptors
in cardiomyocytes, and whether this effect may be another cardio-
protective mechanism of resveratrol in heart failure.
Finally, activation of fetal gene expression is another hallmark of
cardiac hypertrophy. Although a variety of transcription factors are in-
volved in this switch [206], the nuclear factor of activated T-cells
(NFAT) also plays a role [206]. NFAT is a Ca2+-dependent transcription
factor, which exists in the cytoplasm in its phosphorylated state. Cal-
cineurin dephosphorylates NFAT thus allowing NFAT to translocate
into the nucleus where it promotes the transcription of a number ofgenes that encode for proteins involved in promoting cardiac hypertro-
phy [236]. As such, the calcineurin-NFAT pathway has been identiﬁed as
a target for agents designed to inhibit cardiac hypertrophy [205,206]. Of
importance, resveratrol inhibits NFAT in neonatal rat cardiomyocytes
treated with phenylephrine [216] via an AMPK-mediated pathway
and prevents cardiomyocyte growth. This ﬁnding is consistent with an
in vivo study showing that another activator of AMPK also depressed
NFAT signaling and attenuated cardiac hypertrophy in a pressure over-
load rat model [237]. Thus, the ﬁndings with resveratrol indicate that
resveratrol may prevent cardiac hypertrophy through inhibition of pro-
tein synthesis and inhibition of the NFAT pro-hypertrophic genetic
program.
6.2. Clinical studies
Although the anti-hypertrophic nature of resveratrol is well charac-
terized in vitro and in animal models, it is yet to be studied in humans.
To the best of our knowledge, there are no publications involving the
effects of resveratrol treatment in patients diagnosed with heart failure.
In addition, in the clinical study that tested the effectiveness of resvera-
trol in the treatment of patients post-MI (discussed in Myocardial
ischemia and ischemia–reperfusion injury section), cardiacmorphology
was not reported and the effectiveness of resveratrol in reversing cardi-
ac hypertrophy in humans has not been reported [199]. However, in
that same study, cardiovascular function was examined and it was
reported that patients treated with 10 mg/day of resveratrol had signif-
icantly improved diastolic function and a modest increase in systolic
function [199]. As such, these data suggest that resveratrolmay be effec-
tive in the treatment of MI-induced cardiac dysfunction.
7. Diabetic cardiomyopathy
Several studies have shown that diabetes is an independent risk
factor for heart failure, even after corrections for other confounding var-
iables such as CAD, hypertension, dyslipidemia, and obesity [238,239].
The term “diabetic cardiomyopathy” has been introduced to describe
the decline in cardiac function secondary to diabetes [240]. Diabetic
cardiomyopathy is usually associated with early diastolic dysfunction,
late systolic dysfunction, increased interstitial ﬁbrosis, cardiomyocyte
hypertrophy, increased oxidative stress, increased apoptosis, and ab-
normal cardiac energy metabolism [201,241,242]. Since resveratrol
has been shown to possess anti-hypertrophic, anti-apoptotic, and anti-
oxidant properties in cardiomyocytes [58,216], it may target several
pathophysiologic events implicated in the pathogenesis of diabetic car-
diomyopathy. In addition to these direct cardioprotective effects, res-
veratrol has also been shown to improve insulin sensitivity in animal
models of diabetes [243] andmetabolic syndrome [244]. Indeed, resver-
atrol has been shown to protect against diabetic cardiomyopathy in sev-
eral preclinical studies due to both direct cardioprotective effects and
systemic anti-diabetic properties [245], thus widening the scope of the
potential therapeutic use of resveratrol.
Resveratrol treatment has been shown to improve the cardiac func-
tion in streptozocin-induced diabetic rats and mice (a model of type 1
diabetes) in several studies (Table 5). In streptozocin-induced diabetic
rats, resveratrol has been demonstrated to signiﬁcantly reduce blood
glucose levels in treated diabetic rats as compared to non-treated
diabetic rats [246]. Importantly, resveratrol-treated diabetic rats dem-
onstrated signiﬁcant improvement of LV function as compared to non-
treated diabetic animals [246]. In addition, when subjected to an ische-
mic injury, resveratrol treatment resulted in signiﬁcantly reduced
infarct size [246]. These protective effects were associated with an in-
crease in p-Akt, p-eNOS, Trx-1, heme oxygenase-1, VEGF, and SOD in
the hearts of resveratrol-treated rats [246]. Interestingly, the adminis-
tration of L-NAME abrogated most of the cardioprotective effects of res-
veratrol, suggesting that these protective effects are NO-dependent
[246]. Although this study clearly demonstrates the protective effects
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clear whether these effects were due to direct cardioprotective effects
of resveratrol on the cardiomyocytes, or secondary to improved glyce-
mic control by resveratrol. Indeed, in the same model of streptozocin-
induced diabetes, resveratrol has been found to enhance the glucose
transporter (GLUT)-4 translocation through the AMPK/Akt/eNOS sig-
naling pathway in an insulin-independent mechanism in hearts of dia-
betic rats [247], suggesting that GLUT-4 translocation and enhanced
glucose uptake into to the cardiomyocytes may be involved in the pro-
tective effects of resveratrol against diabetic cardiomyopathy. Of partic-
ular interest, resveratrol-induced glucose uptake was also observed in
cultured H9c2 cardiomyoblasts [247], suggesting a direct effect of res-
veratrol on the cells. In addition, AMPK activation has been shown to in-
crease insulin sensitivity in insulin-resistant cardiomyocytes [248].
Since resveratrol is known to activate AMPK in cardiomyocytes [216],
AMPK activation is likely to mediate the protective effects of resveratrol
by both insulin-independent and insulin-dependent mechanisms. To-
gether, these data suggest that the ability of resveratrol to improve the
cardiac function in diabetes may be multifactorial and includes both
NO-dependent and glucose-dependent effects.
In addition to the aforementionedmediators of the beneﬁcial effects
of resveratrol in diabetes, resveratrol has also been shown to increase
survival, improve cardiac function, and decrease interstitial ﬁbrosis in
streptozocin-induced diabetic mice through increasing SERCA2a ex-
pression [233]. Of interest, resveratrol restored SERCA2 promoter activ-
ity in primary cardiomyocytes cultured in high glucose medium [233],
suggesting that the cardioprotective effect of resveratrol is not
completely dependent on its systemic anti-diabetic properties. In an-
other study, resveratrol treatment has been shown to normalize free
fatty acid oxidation, enhance glucose utilization, and reduce biomarkers
of oxidative stress in the hearts of streptozocin-induced diabetic rats
[242]. Similarly, resveratrol treatment was found to improve cardiac
function in streptozocin-induced type 1 diabetic rats, at least in part,
through preserving the functional abilities of cardiac stem/progenitor
cells [249]. Moreover, in streptozocin-induced diabetic mice, both low
(60 mg/kg/day) and high (300 mg/kg/day) dose resveratrol treatmentsTable 5
Effects of resveratrol in diabetic cardiomyopathy.
Model Resveratrol dose
Models of type 1 diabetes
Streptozocin-induced diabetic rats 2.5 mg/kg/day — orally
2.5 mg/kg/day — orally
1 mg/kg/day — orally
2.5 mg/kg/day — IP
1 mg/kg/day or 5 mg/kg/day — IP
Streptozocin-induced diabetic mice About 100 mg/kg/day—mixed with diet
Low dose – about 60 mg/kg/day, high
dose – about 300 mg/kg/day —mixed
with diet
Models of type 2 diabetes
Leprdb diabetic mice 20 mg/kg/day — orally
Streptozocin-nicotinamide model in rats 5 mg/kg/day — orally
Zucker diabetic fatty (ZDF) rat 200 mg/kg/day —mixed with dietimproved function, ameliorated oxidative injury, and reduced apoptosis
in the hearts of treated diabetic mice [250]. The authors have attributed
these effects to the resveratrol-enhanced autophagic reﬂux in a SIRT1-
dependentmechanism [250]. Of importance, the improvement of cardi-
ac function was associated with a dose and time-dependent accumula-
tion of resveratrol metabolites, resveratrol-3-sulfate and resveratrol-3-
glucuronide, in the hearts of streptozocin-induced diabetic rats [251].
Taken together, resveratrol has been shown to protect against diabetic
cardiomyopathy in animal models of type 1 diabetes through several
mechanisms, including those independent from the systemic anti-
diabetic effects of resveratrol.
In addition to type 1 diabetes, resveratrol has also been shown to
improve cardiac function in animal models of type 2 diabetes. In Leprdb
type 2 diabetic mice, resveratrol ameliorated the diastolic dysfunction
observed in diabetic mice [252]. This protective effect was attributed
to a decrease in oxidative/nitrative stress and an increased NO avail-
ability, through inhibition of TNFα-induced NG-κB activation [252].
Although the effect of resveratrol on blood glucose levels was not re-
ported in this study, a separate study in Leprdbmice [253] reported that
resveratrol did not alter bodyweight or reduce hyperinsulinemia or hy-
perglycemia, further supporting the notion that the protective effects of
resveratrol against diabetic cardiomyopathy can occur independent of
its systemic metabolic effects. In agreement with this, in a streptozocin-
nicotinamide model of type 2 diabetes, resveratrol has been shown to
improve LV developed pressure and coronary ﬂow through alleviating
the reduction of cardiac antioxidant enzyme activities, reducing cardiac
oxidative stress, decreasing apoptosis rate, and inhibiting NF-κB activi-
ty [254]. In agreementwith the role of oxidative stress in the pathogen-
esis of diabetic cardiomyopathy, hyperglycemia has been shown to
induce oxidative stress by NADPH oxidase in cultured adult rat cardio-
myocytes [255]. Of interest, Balteau et al. have shown that AMPK activa-
tion reduced ROS production and protected against cardiomyocyte
glucotoxicity [256]. Therefore, AMPK activation by resveratrol may pro-
tect against diabetic cardiomyopathy by reducing oxidative stress.
Moreover, in a Zucker diabetic fatty (ZDF) rat model of type 2 diabetes,
resveratrol has been shown to prevent mitochondrial dysfunction thatDuration Effect Ref
15 days Reduction of blood glucose. Improvement of LV
function. Reduction of the infarction size when
subjected to ischemic injury.
[246]
2 weeks Enhancement of GLUT-4 translocation and
glucose uptake in the diabetic myocardium.
[247]
30 days Enhancement of glucose utilization. Normalize
free fatty acid oxidation. Reduction of
biomarkers of oxidative stress in the diabetic
myocardium.
[242]
8 weeks Improved cardiac function. Decreased unfavorable
cardiac remodeling. Reduced inﬂammatory state.
[249]
1, 3, or 6 weeks Improved cardiac function. Dose-dependent
recovery of all hemodynamic parameters after
6 weeks.
[251]
12 weeks No effect on blood glucose noted on the 12 weeks.
Increase survival. Improve cardiac function.
Decrease interstitial ﬁbrosis.
[233]
16 weeks Improved cardiac function. Ameliorated oxidative
injury. Reduced apoptosis. No signiﬁcant difference
between the low dose and the high dose.
[250]
4 weeks Ameliorated diastolic dysfunction. Decreased
oxidative/nitrative stress.
[252]
4 months Improved LV developed pressure and coronary
ﬂow in diabetic hearts.
[254]
6 weeks Reduced ﬁbrosis, mitochondrial dysfunction,
reactive lipid accumulation, and mitochondrial
ROS.
[257]
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these studies show that resveratrol can also protect against diabetic
cardiomyopathy in models of type 2 diabetes.
In addition to these promising preclinical studies, resveratrol has
been shown to improve insulin sensitivity, improved glycemic control,
reduce oxidative stress, and activate the Akt pathway in type 2 diabetic
patients [74,75,258]. Consistent with this, a recent meta-analysis of 11
randomized clinical trials has demonstrated that resveratrol signiﬁcant-
ly improves glycemic control and insulin sensitivity in diabetic patients
[259]. Interestingly, although resveratrol has been shown to provide the
most pronounced cardiovascular beneﬁts in clinical trials that enrolled
patients with type 2 diabetes [74,75], there is still no clinical data
about the protective effect of resveratrol against diabetic cardiomyopa-
thy. Since diabetic cardiomyopathy develops late after the diagnosis of
diabetes [260], long-term clinical trials are warranted to evaluate the
effect of resveratrol in diabetic cardiomyopathy.
8. Chemotherapy-induced cardiotoxicity
Several chemotherapeutic agents (e.g. doxorubicin, sunitinib, cis-
platin, and trastuzumab) have been demonstrated to cause severe
acute and chronic cardiotoxic effects that may lead to cardiac dys-
function and heart failure [202,203]. A number of studies have dem-
onstrated that resveratrol protects against doxorubicin-induced
cardiotoxicity in a variety of animal models (Table 6) [261–266].
Multiple mechanisms have also been proposed to explain the protec-
tive effect of resveratrol against doxorubicin-induced cardiotoxicity.
Since ROS generation has been shown to be a major contributor
to doxorubicin-induced cardiotoxicity [267], several studies have
attributed the cardioprotective effects of resveratrol to its ability to
induce endogenous anti-oxidant enzymes such as SOD [262,263,
268–270], catalase [263,268,270], NADPH quinine-oxidoreductase-
1 [268], and heme oxygenase-1 [271]. In addition, resveratrol has
also been shown to protect against doxorubicin-induced cardiotoxicity
through activation of AMPK [272], inhibition of p70S6K-mediated
autophagy [273], and activation of SIRT1 [269,274]. We have also
shown that resveratrol can protect against doxorubicin-induced
cardiotoxicity by increasing the expression of SERCA2a, mitochondrial
electron transport chain complexes, mitofusin-1, and mitofusin-2
[262]. Since resveratrol protects against doxorubicin-induced cardio-
toxicity through multiple mechanisms, not only through its anti-
oxidant properties, resveratrol may be a better candidate to protect
against doxorubicin-induced cardiotoxicity in cancer patients than
some other anti-oxidant compounds that failed to offer such protection
in clinical trials [275].
Although very promising effects have been achieved with resvera-
trol in animal models of doxorubicin-induced cardiotoxicity, there is
much less research into the protective effects of resveratrol against
cardiotoxicity caused by other chemotherapeutic agents. Wang J et al.
have shown that resveratrol alleviated cisplatin-induced myocardial
damage in a dose-dependent manner demonstrated by an improve-
ment in histological appearance of the myocardium and normalization
of markers of myocardial damage such as creatine kinase (CK) and
lactate dehydrogenase (LDH) [270]. Resveratrol has also been shown
to protect against arsenic trioxide-induced cardiotoxicity in mice and
rats [276,277]. The protection against cisplatin and arsenic trioxide-
induced cardiotoxicity has been attributed to the increase in the
endogenous anti-oxidant enzymes activity namely, SOD, catalase, and
glutathione peroxidase [270,277], in addition to activation of the anti-
oxidant NRF2-heme oxygenase-1 pathway [276], suggesting the impor-
tance of the anti-oxidant properties of resveratrol in these models as
well. Recently, an in vitro study has reported that resveratrol protects
against sunitinib-induced hypertrophy in H9c2 cells [278]. The authors
of that study proposed that resveratrol prevents hypertrophy by antag-
onizing the aryl hydrocarbon receptor (AhR) and inhibiting CYP1A1 en-
zyme [278], suggesting that resveratrol may also protect againstchemotherapy-induced cardiomyopathy through its AhR-antagonistic
properties. The translational potential of these ﬁndings is very prom-
ising, since resveratrol has also been shown to augment the chemo-
therapeutic activity of several anti-cancer agents including
doxorubicin [265,279,280]. Nevertheless, there is very limited infor-
mation about the cardioprotective effects of resveratrol in cancer pa-
tients treated by doxorubicin or other cardiotoxic chemotherapeutic
agents.
9. Arrhythmia
Cardiac arrhythmia remains a serious medical problem despite
intensive research in this area [281]. For instance, atrial ﬁbrillation
(AF), which is the most common cardiac arrhythmia, remains a sig-
niﬁcant risk factor for stroke, heart failure, and cardiovascular-
related mortality [282]. Despite the availability of a number of anti-
arrhythmic medications, the safety proﬁle of most of them is far
from optimum [283]. Therefore, the discovery that resveratrol also
possessed anti-arrhythmic properties is important for the clinical
utility of resveratrol. That said, the anti-arrhythmic effect of resvera-
trol is not as well-studied. The studies that have been performed
show that a single IV dose of resveratrol (5, 15, 45 mg/kg) caused a
signiﬁcant anti-arrhythmic effect in three models of arrhythmia:
aconitine-induced, ouabain-induced, and coronary ligation-induced
arrhythmias [284]. In the coronary ligation-induced arrhythmia
model, the anti-arrhythmic effect of the highest resveratrol dose
was comparable to that of lidocaine, a known anti-arrhythmic drug
[284]. Similarly, resveratrol suppressed ischemia–reperfusion-induced
ventricular arrhythmia in a Langendorff-perfused rat heart [285]. Lastly,
chronic oral resveratrol treatment (5 mg/kg/day for 4 weeks starting
one week before MI) signiﬁcantly suppressed MI-induced ventricular
tachycardia and ventricular ﬁbrillation and improved acute-phase
survivals in rats following MI [158].
Several in vitro studies have demonstrated the electrophysiological
properties of resveratrol. The anti-arrhythmic effect of resveratrol has
been attributed to Ca2+ channel antagonism and KATP channel opening
[158]. Other studies have shown that resveratrol signiﬁcantly shortened
action potential duration and the peak L-type Ca2+ current in guinea-
pig ventricular myocytes [284,286]. Zhang et al. have attributed the
inhibition of L-type Ca2+ channels by resveratrol to the inhibition of
protein tyrosine kinase in rat cardiomyocytes [287]. On the other
hand, Chen et al. have shown that resveratrol prolonged action potential
duration, inhibited inward sodium and calcium currents, and increased
cardiac refractory period [285]. Qian et al. have demonstrated that res-
veratrol inhibited H2O2-induced augmentation of late sodium current
in rat ventricularmyocytes [281]. Similarly, Li et al. have shown that res-
veratrol inhibits oxidative stress-induced arrhythmogenic activity in
rabbit ventricular myocytes through inhibition of late Na+ current and
L-type Ca2+ current [288]. Of interest, resveratrol inhibited delayed
after depolarization induced by ouabain in guinea pig papillary muscle
independent of its NO or estrogen-modulating effects [289], suggesting
that the anti-arrhythmic properties of resveratrol may be distinct from
its other cardioprotective effects. To optimize the anti-arrhythmic
potential of resveratrol, a new resveratrol derivative has also been
shown to be a multi-functional molecule that targets key pathways
involved in the pathogenesis of atrial ﬁbrillation [282]. To the best of
our knowledge, there are no human studies that investigated the anti-
arrhythmic effect of resveratrol.
10. Discussion
Herein, we have reviewed a variety of CVDs and have discussed how
resveratrol has been shown to alter their pathophysiology. In general,
preclinical studies have yielded promising and, in some cases, exciting
results for the prevention and/or treatment of hypertension, ischemia–
reperfusion, MI, stroke, arrhythmia, dyslipidemia, cardiac hypertrophy,
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in animals do not necessarily translate to human studies, so care should
be taken in the interpretation of the effectiveness of resveratrol in treating
humanswith CVD. Indeed, clinical studies involving resveratrol are either
inconsistent or not as promising as the preclinicalﬁndings reviewedhere-
in. While several positive clinical studies have been published [74–76,
199], other recent clinical studies have refuted the beneﬁcial effects of res-
veratrol for the treatment of certain cardiovascular disorders [78,139,
290]. Importantly, a prospective cohort study demonstrated that total uri-
nary resveratrol metabolite concentration was not associated with in-
ﬂammatory markers, CVD, or cancer; or predictive of all-cause mortality
[291], thus suggesting that there is no beneﬁt to resveratrol supplementa-
tion in humans. However, this study investigated these outcomes in older
community-dwelling adultswho consume resveratrol as part of their reg-
ular diet and the amount of resveratrol consumed from the dietary
sources is much lower than the therapeutic doses of resveratrol used in
clinical trials. Since most of the effects of resveratrol are dose-dependent
[292], the negative ﬁndings from the observational study [291] are prob-
ably not representative of the effects of resveratrol when administered as
a nutraceutical. That said, two other clinical studies showed that resvera-
trol blunted some of the protective cardiovascular effects of exercise in
aged men [293,294], further raising doubt on the effectiveness of resver-
atrol in humans. Therefore, it is important to address the challenges that
face the translation of the very promising preclinical results to real-
world clinical beneﬁts of resveratrol.
Perhaps one of the largest challenges associated with resveratrol
is its low bioavailability [295–297]. Although resveratrol is highly
absorbed when given orally, it has a very low bioavailability due to
rapid metabolism to its glucuronide and sulfate conjugates [298].
Administration of approximately 25 mg resveratrol results in plasma
concentrations that are between 1 and 5 ng/mL [299], and administra-
tion of even larger amounts, up to 5 g, still only yield 500 ng/mL
(2 μM) [300]. This has resulted in the concept of the “resveratrol para-
dox”, which describes amolecule with a very low plasma concentration
that has multiple biological effects [301]. To explain this, a number of
theories have been proposed ranging from resveratrol concentrating
in certain organs [302] to the evidence that shows the conversion of
sulfated conjugates of resveratrol back to the parent compound in cer-
tain cell types [303]. Although this latter concept presents a possibleTable 6
Effects of resveratrol in chemotherapy-induced cardiotoxicity.
Model Resveratrol Dose Duration
Chronic doxorubicin-induced cardiotoxicity
in Balb/c nude mice
10 mg/kg/day by oral gavage 5 weeks, sta
before doxo
injection
Chronic doxorubicin-induced cardiac
dysfunction in C57BL/6 mice
4 g/kg diet 8 weeks
Chronic doxorubicin-induced cardiotoxicity
in rats
20 mg/kg/day by oral gavage 4 weeks, sta
before doxo
Chronic doxorubicin-induced cardiotoxicity in
rats
10 mg/kg/day IP 7 weeks, sta
before doxo
Sub-acute doxorubicin-cardiotoxicity in rats 5 mg/kg every other day 1 h
before and 2 h after
doxorubicin
injection
5 days
Acute doxorubicin-induced cardiotoxicity in
rats
30 and 120 mg/kg/day IP 3 days
Acute doxorubicin-induced cardiotoxicity in
rats
15 mg/kg IP Single dose
Sub-acute cisplatin-induced cardiotoxicity in
rats
5, 15, 45 mg/kg/day by oral
gavage
10 days, sta
before cispl
Sub-acute arsenic trioxide-induced
cardiotoxicity
in BALB/C mice
3 mg/kg IV every other day 3 doses, one
arsenic triox
administrat
Sub-acute arsenic trioxide-induced
cardiotoxicity
in rats
8 mg/kg IV every other day 4 doses, one
arsenic trioxexplanation for the in vivo results observed for resveratrol for the treat-
ment of CVD, it needs to be investigatedwhether or not cardiomyocytes
(or other cardiovascular target cells) also have the ability to transport
the sulfated conjugates of resveratrol into the cell to be metabolized
back to the parent compound [303]. Of interest, a recent study has
demonstrated the accumulation of resveratrol metabolites, resveratrol-
3-sulfate and resveratrol-3-glucuronide, in heart tissues of diabetic rats
in a dose and time-dependent manner [251]. The myocardial accumula-
tion of these metabolites was associated with improvement in cardiac
function [251], raising the possibility that the pharmacological effects of
resveratrol are mediated, at least in part, through active metabolites.
Due to the poor bioavailability of resveratrol, there remains a ques-
tion as to what dose should be used for clinical studies? In the animal
studies reviewed herein, effective doses have ranged from as low as
0.1 mg/kg/day up to 800 mg/kg/day (see Tables 1–6). Similarly, in
clinical studies, doses of resveratrol range from 10 mg/kg/day to
1000 mg/kg/day (Table 7). This issue of dose is particularly important
as several resveratrol effects are dose-dependent (discussed earlier).
Furthermore, since resveratrol may exhibit a hormetic dose–response,
this further complicates a dose selection for clinical studies [304]. An-
other important and related question is what method of administration
should be chosen? Although resveratrol is poorly soluble in aqueous
solutions [305], some preclinical studies administer resveratrol in the
drinking water, which may create dose variability issues. How this
hurdle will be overcome in clinical trials has yet to be addressed but
the poor solubility of resveratrol may be enhanced by increasing its
aqueous solubility via microparticulate systems, cyclodextrin com-
plexes, nanocarrier systems, or even vesicular systems (reviewed in
[297]).Whether or not this will improve the effectiveness of resveratrol
in clinical studies has yet to be tested.
Since the clinical data for the effectiveness of resveratrol are still
limited, it is difﬁcult to conﬁrm or refute its potential beneﬁcial effects
in the treatment of humans with CVD. Although we have a few
human trials, the cardiovascular effects of resveratrol have never been
tested in a large double-blinded placebo-controlled clinical trial
(Table 7) and the largest published clinical trial has only enrolled 66 pa-
tients [75]. Moreover, most of the beneﬁcial cardiovascular effects of
resveratrol have occurred in clinical studies that had a primary focus
on diabetes and/or other metabolic diseases and CVD was not theirEffect Ref
rting one week
rubicin
Alleviated doxorubicin-induced cardiac damage (decreased
CK and LDH activity), decreased doxorubicin-induced
cardiomyocyte apoptosis
[289]
Improved LV function, improved exercise capacity [262]
rting 2 weeks
rubicin
Alleviate doxorubicin-induced oxidative stress, inﬂammation,
apoptosis, and ﬁbrosis.
[261]
rting 2 weeks
rubicin
Alleviated doxorubicin-induced cardiac dysfunction. [263]
Alleviated doxorubicin-induced bradycardia and QTc
prolongation.
[266]
Alleviated doxorubicin-induced oxidative stress and
histological
damage.
[264]
Alleviated doxorubicin-induced histological damage. [265]
rting 5 days
atin
Alleviated cisplatin-induced myocardial damage in a
dose-dependent manner
[270]
hour before
ide
ion
Alleviated arsenic trioxide-induced QTc prolongation,
myocardial damage
[277]
hour before
ide
Improved arsenic trioxide-induced myocardial damage [276]
Table 7
Cardiovascular effects of resveratrol in clinical studies.
Study population Study design Resveratrol dose Duration Cardiovascular Effect Ref
Patients with type 2 diabetes (n = 66) Randomized placebo-controlled
double-blinded parallel
1 g/day 45 days Reduction of SBP and LDL, increase in HDL,
No change in total triglycerides and total
Cholesterol.
[75]
Patients with type 2 diabetes (n = 62) Prospective, open-label, randomized 250 mg/day 90 days Reduction of SBP, total cholesterol, LDL,
and hemoglobin A1c
[74]
Healthy obese men (n = 11) Randomized, placebo-controlled
double-blind crossover
150 mg/day 30 days Reduction of SBP, plasma triglycerides levels. [76]
Patients with metabolic syndrome (n = 34) Open-label, randomized 100 mg/day 90 days Improved ﬂow-mediated dilation. No effect on BP or
lipid proﬁle.
[79]
Overweight older adults (n = 32) Double-blind, randomized,
placebo-controlled trial
300 mg/day
1000 mg/day
90 days No effect on blood pressure. [290]
Healthy obese adults (n = 28) Randomized, placebo-controlled
double-blind crossover
75 mg/day 42 days Improved ﬂow-mediated dilation. No effect on
blood pressure.
[82]
Healthy obese men (n = 24) Randomized, placebo-controlled,
double-blinded, and parallel-group
500 mg/day 28 days No effect on blood pressure. No effect on
lipid proﬁle.
[139]
Older subjects with impaired glucose
tolerance (n = 10)
Open-label 1–2 g/day 28 days No change in BP or plasma lipids. A trend
toward improved post-meal reactive
hyperemia index.
[322]
Post-infarction Caucasian patients with
stable CAD (n = 40)
Double-blind, placebo-controlled 10 mg/day 90 days Reduced LDL, improved ﬂow-mediated dilation
and LV diastolic function. A trend toward
improved LV systolic function.
[199]
Patients with stable angina pectoris Randomized, double-blinded,
active-controlled, parallel
20 mg/day 60 days Signiﬁcant reduction of C reactive protein and NT-
proBNP.
Slight improvements in lipid proﬁle from
baseline. Improvement in quality of life.
[194]
Over-weight/obese men or postmenopausal
women with borderline hypertension
(n = 19)
Double-blind, placebo-controlled,
randomized crossover
30, 90, 270 mg Single ingestion Improved ﬂow-mediated vasodilation one hour
after resveratrol ingestion in a dose-dependent
manner.
[323]
Non-obese, post-menopausal women
(n = 45)
Randomized, double-blind,
placebo-controlled
75 mg/day 84 days No effect on blood pressure or plasma lipids. [78]
Healthy adult smokers (n = 50) Randomized, double-blind,
placebo-controlled, crossover
500 mg/day 30 days Signiﬁcant reduction in triglyceride
concentration. No effect on blood pressure.
[136]
Overweight/obese men with mild
hypertriglyceridemia (n = 8)
Randomized, double-blind,
placebo-controlled, crossover
1 g/day for the
ﬁrst week,
2 g/day for the
second week
14 days No effect on plasma triglycerides or cholesterol
levels.
Reduction in intestinal and hepatic lipoprotein
particles production.
[138]
Healthy adults (n = 22) Randomized,
double-blind, placebo-controlled,
crossover
Randomized, double-blind,
placebo-controlled, crossover
250 or 500 mg– Single dose Dose-dependent increase in cerebral blood
ﬂow during task performance — pattern
suggests the involvement of NO.
[153]
Healthy adults (n = 23) Randomized, double-blind,
placebo-controlled,
within-subject
Single dose Increase cerebral blood ﬂow. [152]
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were not measured. In addition, clinical studies involving resveratrol
have been limited to investigating the short-term effects of resveratrol,
not its long-term cardiovascular outcomes. Since the development of
some CVDs such as atherosclerosis and cardiac hypertrophy occurs
over many years [97,306], long-term studies are warranted to examine
the beneﬁcial effect of resveratrol on the pathogenesis of these diseases.
In addition to effectiveness, long-term clinical trials are needed to con-
ﬁrm the long-term safety of resveratrol, which is still unknown. Taking
into account the multitude of molecular targets affected by resveratrol,
it is very hard to predict its long-term adverse effects, and its interaction
with speciﬁc disease states. In addition to compound safety, the
potential drug-interaction with resveratrol should also be considered,
since resveratrol has been shown to inhibit the phenotypic indices of
the cytochrome P450 (CYP) 3A4, CYP2D6, and induce that of CYP1A2
in human subjects taking 1 g of resveratrol once daily for 4 weeks
[307]. The effects that resveratrol has on these enzymes suggest
that further studies to investigate its efﬁcacy and safety are urgently
needed.
Adding some confusion to our understanding of the effectiveness of
resveratrol in humans is the use of a mixture of polyphenolic com-
pounds instead of pure resveratrol in some studies [137,308–311].
These studies are also creating some confusion about whether the ob-
served effects aremainly due to resveratrol or due to other polyphenols.
Although some clinical studies havemeasured the resveratrol content in
the grape extract, and administered a resveratrol-free grape extract as acontrol, there is still a possibility that other polyphenols synergize the
effects of resveratrol [309]. Moreover, some meta-analyses combine
the data from studies that used pure resveratrol with data collected
from studies that used a polyphenolic mixture [80], which makes the
ﬁnal conclusion of thesemeta-analyses also difﬁcult to interpret. Unfor-
tunately, the large controlled trials needed to conﬁrm the effects of res-
veratrol in the treatment of CVD have not been performed.
In an era of personalizedmedicine, resveratrol should not be expect-
ed to treat all CVDs in all patient groups. Therefore, it is important to
identify and target patient groups with speciﬁc CVDs that will respond
themost to resveratrol. For example, it has been proposed that the effect
of resveratrol on insulin signaling is dependent on the metabolic status
of the patient (i.e. insulin resistant or not) [312] and a similar dependen-
cy may be the case with the potential cardiovascular beneﬁts of resver-
atrol. Indeed, the beneﬁcial cardiovascular effects of resveratrol were
mostly observed in diabetic patients [74,75], suggesting that the cardio-
vascular beneﬁts of resveratrolmay bemore readily apparent in this pa-
tient population where CVD is a common co-morbidity. In agreement
with this notion, resveratrol treatment has been shown to signiﬁcantly
lower systolic BP in a recent meta-analysis of clinical trials investigating
the effect of resveratrol in patients with type 2 diabetes [313]. As such, it
will be important to perform clinical trials that compare the cardiovas-
cular effects of resveratrol in diabetic patients to its effects in non-
diabetic patients with identiﬁed CVDs.
In conclusion, preclinical studies using resveratrol have demonstrat-
ed several convincing beneﬁcial cardiovascular effects. In some
1171B.N.M. Zordoky et al. / Biochimica et Biophysica Acta 1852 (2015) 1155–1177instances, these ﬁndings have provided the foundation needed for test-
ing resveratrol in humans. Unfortunately, the clinical studies investigat-
ing the beneﬁcial cardiovascular effects of resveratrol are still limited
and there is a need for large, well-controlled clinical studies to study
the effect of resveratrol in patients with deﬁned CVDs. Until that time,
the beneﬁts of resveratrol in the treatment of patients with CVDs will
remain as is; holding great promise but not yet proven.
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